{
  "id": "221e51b8-4418-4472-8d20-e12bbf705612",
  "appName": "opentargets_agent",
  "userId": "user",
  "state": {
    "safety_agent_report": "Excellent. I have now gathered all the necessary data to provide a comprehensive safety assessment for the ESR1 gene target. I will now synthesize the detailed safety liabilities and the quantitative prioritization scores into a final report.\n\n### **1. Safety Summary of ESR1 (Estrogen Receptor 1)**\n\n**Overall Assessment:**\nESR1 is a well-established therapeutic target for ER-positive breast cancer. Its safety profile is extensively characterized and reflects its critical role in hormonal regulation. The associated risks are primarily on-target, predictable, and directly related to the inhibition of estrogen signaling. While significant, these adverse effects are generally considered manageable within the context of cancer treatment.\n\n---\n\n**Key Safety Liabilities:**\nModulating ESR1 carries known risks. For treating ER-positive breast cancer, the most relevant liabilities stem from **inhibiting** the receptor's function:\n\n*   **Endocrine and Reproductive Effects:**\n    *   **Common:** Hot flashes, vaginal atrophy, and breast atrophy are frequent side effects due to reduced estrogenic activity.\n    *   **Development & Fertility:** Targeting ESR1 can impact sexual development and lead to decreased fertility or azoospermia (absence of sperm).\n\n*   **Musculoskeletal Effects:**\n    *   **Bone Health:** Inhibition of ESR1 signaling is strongly associated with bone mineral density loss and an increased risk of **osteoporosis**.\n\n*   **Cardiovascular Effects:**\n    *   **Thrombosis:** While more commonly associated with ESR1 *agonists*, a general risk of thrombosis (blood clots) is a noted liability for drugs targeting this pathway.\n    *   **Cholesterol:** Modulation can lead to changes in cholesterol and triglyceride levels.\n\n*   **Oncogenic Risk:**\n    *   Conversely, *activation* of ESR1 is linked to an increased risk of **endometrial and ovarian cancers**, underscoring the importance of using antagonists or degraders in breast cancer therapy.\n\n---\n\n**Quantitative Risk Assessment (Based on Target Prioritization Data):**\n\n*   **Known Safety Events (`hasSafetyEvent` = -1):** This score confirms that targeting ESR1 is associated with known clinical adverse events, which aligns with the extensive list of liabilities above.\n*   **Genetic Intolerance (`geneticConstraint` = -0.73):** This negative score indicates that the ESR1 gene is relatively intolerant to mutations in the general population, suggesting it plays an essential biological role. Targeting such genes can sometimes carry a higher risk of significant physiological disruption.\n*   **Mouse Model Phenotypes (`mouseKOScore` = -0.94):** The strongly negative score indicates that knocking out the ESR1 gene in mice results in severe, system-wide phenotypes, particularly related to sterility and developmental abnormalities. This provides strong preclinical evidence for the on-target toxicities observed in humans.\n*   **Tissue Specificity (`tissueSpecificity` = 0.5):** ESR1 has moderate tissue specificity, with primary expression in reproductive tissues, breast, bone, and certain areas of the brain. This explains the specific pattern of on-target effects.\n\n---\n\nThis completes the safety assessment for the ESR1 target. My task is now finished, and I will hand the results back to the **Principal Investigator** for the next step in the workflow.",
    "biologist_report": "Excellent. I will now provide the biological rationale for targeting ESR1 and the scientific reasoning for using a combination therapy strategy in ER-positive breast cancer, as requested by the Principal Investigator.\n\n### **Biological Rationale for Combination Therapy in ER-Positive Breast Cancer**\n\n**1. The Role of ESR1 as a Primary Driver**\n\n*   **Mechanism:** The Estrogen Receptor 1 (ESR1) protein is the defining feature of ER-positive breast cancer. It acts as a **ligand-activated transcription factor**. When the hormone estrogen binds to ESR1 in a cancer cell, the receptor activates and moves into the nucleus. There, it switches on a specific set of genes that drive the cell to grow, proliferate, and survive.\n*   **Therapeutic Implication:** Because estrogen signaling via ESR1 is the fundamental engine of tumor growth in this subtype, therapies are designed to cut this fuel line. Drugs like **Tamoxifen** and **Fulvestrant** work by either blocking estrogen from binding to the receptor or by promoting the receptor's complete degradation, effectively shutting down this pro-growth signaling pathway. This approach is known as endocrine therapy.\n\n**2. The Scientific Rationale for a Synergistic Combination with CDK4/6 Inhibitors**\n\nWhile endocrine therapy is effective, cancer cells are notoriously adaptive and often develop resistance. A common way they do this is by finding alternative ways to activate the cell's division machinery, even when ESR1 signaling is blocked. This is where the synergy with CDK4/6 inhibitors comes in.\n\n*   **The Cell Cycle Connection:** One of the main downstream effects of ESR1 activation is the promotion of the cell cycle. Specifically, ESR1 signaling increases the production of a protein called Cyclin D. Cyclin D then partners with and activates two key enzymes: **Cyclin-Dependent Kinase 4 (CDK4)** and **Cyclin-Dependent Kinase 6 (CDK6)**.\n*   **CDK4/6 as the Gatekeeper:** The CDK4/6-Cyclin D complex acts as a critical gatekeeper that controls the cell's decision to divide. When active, it phosphorylates the Retinoblastoma (Rb) protein, which in turn releases the brakes on the cell cycle, allowing the cell to transition from the G1 (growth) phase to the S (DNA replication) phase, committing it to division.\n*   **Rationale for Synergy:**\n    1.  **Dual Blockade:** Endocrine therapy (targeting ESR1) shuts down the primary \"request\" for cell proliferation. A CDK4/6 inhibitor blocks the core \"machinery\" that executes that division. By targeting both, you create a much more robust and durable blockade.\n    2.  **Overcoming Resistance:** If a cancer cell develops a mutation that allows it to activate the CDK4/6 pathway without relying on ESR1, endocrine therapy alone will fail. However, a CDK4/6 inhibitor will still be effective because it blocks the pathway further downstream.\n    3.  **From \"Brakes\" to \"Full Stop\":** Targeting ESR1 puts the brakes on the cancer cell's growth. Adding a CDK4/6 inhibitor essentially puts a wall in front of the cell, preventing it from moving forward in the cell cycle. This combination has been clinically proven to lead to a significantly longer period of disease control compared to endocrine therapy alone.\n\nIn summary, combining an ESR1-targeting drug with a CDK4/6 inhibitor is a powerful synergistic strategy because it attacks two distinct but critically linked nodes in the same cancer-driving pathway. It both shuts off the primary growth signal and disables the core machinery responsible for cell division.\n\nMy analysis is complete. I am now passing control back to the **Principal Investigator** for the final integration and summary."
  },
  "events": [
    {
      "content": {
        "parts": [
          {
            "text": "are there suitable drugs for breast cancer that are synergetic and safe"
          }
        ],
        "role": "user"
      },
      "invocationId": "e-e939c97b-38f1-4af0-9d7e-2fd9a872743e",
      "author": "user",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "0ebf2248-e067-4924-92a7-f3a56fa02eb7",
      "timestamp": 1761138880.613296
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CpstAdHtim-C7j30vTbiLzjARudx14DTj16kEmoQHVq36XFYzl7AWaKEOULzO4V6G7A55EOPVXthy2HhLIQ4eXyqiio1_Pt4PrzQ2J8sTOpoiAeScGgk16-Ml7og-4pKKzdZd4feHfC78EXZ2nVqQSUSpRC598os9ORlLmE0EqXhBmWvIKRQ9h35tkGrZsYCAeW_mU1KBHJ8BXPXDtGMLyXyGmpoxyuUa8tGVAUHptFH6LoSmK0rPFpLNor622-FiR9neRnXjJk7qIx3aEPjRN1NKx92kItOWXpSs9kK0hTEdCvnu_KGi_LUC64GEo_j77B9bKc19c7keedyUe5IeERvYJm0JXoUbc0biJaGlmEMAs9uXqBHUqgH0dFiw0tKX1paKR9toefNkPiHd6SKcPR9tl_3J4cHpVCjO5xQU0BYiK3aYVe3v12usaHHCbSRd1g_VrtG3Y-d1M0GrNhakd40V2lOh4YHgWOmMJYC0zxIS2k0F7R7XtDR-pFaADpGn8zVh7htlkQtf94TkiM522NeZXTbZg3tfLiN9tHsocClM3NCog6YutPc7hWmm_3ZAAO0U8JjNWeQZf6Wpc-xPp-mg4tTm-D8TbF-oAlgXbeLqBYGwXH-5yAsbquC4m3sVk-1mRmpdqrwTZkrb-6-mCsT31OX4rLYhj_YrwezKyUqC2pMaz9Udb5C-Tzi92V0MZGngamUEtuTvUnX1atvCKEZKbTNt3cl9U1BmWa-gsfNFiUbVvbC1JwoJ0u8jGETfosX5Tmx9OAk3G2qolzaeCiQTBhcLYI4hNgll3GlVxjPm2DyfvIxYZb1QYEzAWhrmO9qwKvmagLeOjBG_nNb7OIDVmcYUxNHKJ0IQxFeryN_lqeTtpUNbZqObJs_k40EhTYk-6D0_atXBFw-pgU6nlNVhgOldNLpRkwR0X0MUNlaDk2_x90MZO3DVyqrg5yMnEasR05Tf_kNegV561L4ZOJz89PyUC28cvp8TxQ8YvfybP2zcYH97vkOPaS5rS0PMvlamKPE8ukeqV0hBD7WDa18DsbIpLE7Vbfd1wPgGWLCX57Z-DU5Qmc76rBtIpD8L5vsBFqQZXC0cX7pZderptDn78WgxiuHHr0fEG7btLpkYXwFYYsDHaxnb4e2EgUginLjgVqydF2mtQvHFR3HLzPb_jTkoD_0Wa1xR-WcOWXgChMGbgpqOXG8LZndHqE750YcwDLo6IXyeQ6QfGDE8vBwRE54P30VNlMM6i19KhDUFxx5EhCBue5YPz32zDpsV-s3VIQ2Ktrnpd8fyfHfzTGYKBgkDVsTSf9i25OqRN9Ksg0tEI-LPzyR9S_ZU4K4d3Y60TKd1-Jlld-jEoph0Qm9FY1OFGTUw_wJJjKB3g_GlAFy47-3zYd4FqANItgfuqxRpr0rDyZXJUFslhReC4OuGZ5eqjEZIemoK39NC1hg3odAAkqDgEFty3ksswEPovgJrpxm3LFOsome5k2TdAoJT9QQSO7xNIlDrOTFgkXTPyqJR_uzYOesYWadNSU3HZyRlXUOmfsec98BSy0Cva9AWYL4WvDJZnJwrkMvtJgeiSe8c4IV4cf293l0KeJ3Z3TGuTWQnxbUqQAq5Hfe1_VjRh7NxwUd_vdTC-6iyUlFQmm49_HUTu8Sq-XCm6-l59HqDJt6A6pumht5MckFruYwy3dvIovEfN4f-Wb_OxhzP44Uk60BTiTDsfeh9QBTdfZQ7CewikuevTOFGrjua5iWzize8Xn01NV5UdanOWCXob0NmB92fLqyKA_I5qCX9cYITNQQM9xleeq-0mZnP-u_5cuOrwMAZSAURzZ0yKPKCOaQDdupck6DTUCIUkDZQ_uGcmBW5ZtUCukvilQ5V-MMXK9O-acT9aWl9VM5sFohqrh5s6LYr90e816XAyid-RmH3L2agnge9aDCnrHJMbH2qaz9n50GWd-impJgkAl1U2WdicsvcyiG3U4zElYBenlXbyXRW0kQA92iwrhxZi40vDAMEcQ0BHIyfktGR4zLftmUurOdASfcsSMe5IcY8ul8ltxoNKPLMCbifG4ZDxUR6BOLY9PqPkuwjuWCNnmmqIYxW8XR_DSSlcP-pYJvidTec_J0JEH5EHQg601avpP7L-2_cXg3BAvUWaBVZlxVx-b6QtzcOVcOUWDWvJwgNQQennH6J7X4iQTM-N4A3SYw6aFTNbpEKdCjdDhcbDhbZI38JJ4hybiQpCvTLvnAmWVkYilxfqwE19D4oLo0Giij_Qe9Ql0CgWtAUBmrDrX9KWBZAXrS380KrO22bZa-m9AKqAXL2tw3BPC8L0u1TpG7prD8zjLN8Dzas-PXIyRgU_NEtALPliSmZsfBm6rz4JoINED3KAx1sNQjaeh92hhyAEoM5NLcnnt1vr6iWGuORmNETFby7S9sB-ntlPE0ySogc6V9X6soVaLxSJegg7cJs13TCVm8tb4mL3AZMlBJjyZH2ZQKUSBkDy8GuYbhfXIyl3GIVvaqF6Gj-tIkSUbbJVGtr3kTRUioJ4qXz2UszVjix4rS0X__mOW4kvcqBZMlmurGoDuUe8yuzuffFpDo8S1vaarriczYGSodZ14gg_IHg1lQJ1uCXXfvAUPnUNWMWP9bAp6vQ5p2c5_jKWM2wKkCJ7YsCCauUexCKrlk9o3sY0esVWeByzZzIi7Hjm5QtuueD-yFGRGIe_RUU2WdKpCSaG2NlNSFg3piTKHOff38GCUU5ErEI42L2FBrIfkKwn2kZC8uH5iY35yw6MPMP9L5pFCxv14g9t4trMLsWDP6NiklMSF8XGzBX__4H8bAt1BG09TA0_dpoouriQQvfVje7WqocOfnlQ1jZ0qh7UWP6fD8UgH2me5lwQedDUmThu2zSw15q7xP_QX3YtuUny1QhYP9k14VQMvLZCvmB_kPjnsVM4xVjpZcaq60ta6xpxSqQbstIjY3H9RCIkxYgFHnbmhmwjHoWN_h8bFhJYVr6ngALTopkhAy63hwKu28mQTr6CWnrgPj_xr_ObxsSNG313acb1sCWr4J8it1A0nfoh_ifOjtyIwOkwLCLIBxZSVy5rgqaabyX_YPDeOBDoys_HkOY8L1TIk5H1y_td-B1mvQPTouQbgfYmakvaEL7ZhDgKhZzUii1NLTPGLHJTLIQmfDYbsgruJn3Rnf-6fQ6Cts1yYBZw3JmN1FSBhUy0VXZmZefU7BPcwBssg6Ag6adgDZ_vrrz-rAS4a-royQrnT2iXBVqGT14BKJKIBKWcJfT01_46wK4RG1jLFD0yUI24Xgcj0LH9Xb9rVKusQ21loTxqQwyCv9DX1xItTXloK9qyAzy_8lAeUSUBMO0nVIAxZDz3UNTr8tpw99wGkiBbW6Ypm7cCsmavHhPGlRJmvqgCbVnu_c9NQcMLfN85L4wgFAxieYlP1XM49FZp3eBjmIV4nZwHBncfhV7qO9KYwbZN2O2edEjh3YjbsJf2zJoOeAouzYfO85hFpwGx6mAQc0cwx_QoYabEhg781h8PnSEI0T_-RCxmu7sKgYpIvJ5HZaOHSqNgCWfDEu44MiXIEFDi4YkqN1IB5Os3IjCHENXzD9HR1H8RWanQYJLTNPNqoRD3xtIQg1hiBqxoKCDm2sXEDRPWf61qcqcWew7w1TwHPqDOfZFlwUJw6BiZk1laYdXerbHpRkiY6zlw6lwl4-6rIVkIjWwx_gkia6VV37wwjUWbyvMJJOz37yzQjhvz6umlYqoq-lLZ6zJfQXqVe0gv4D8TR8LaFpkLbeCN_zsnelXGEeJ1PzVFkuQt4itaK0lp6_ktq-hwpGyhTjT7W9_xF41itFzWDpQw5c-4yhI48XUeIcJbqH4w6CHCSHLa6AO11j4zK6xIME1CUNMC8tThTnrHH99zrCVpowfsZY-tnvaupDz3JL_xs9TC7g9hVl8KLrjW8FCeP9zTeboaXCegjd7eEFNVuTSmRqGTQyJ60DRNiYkWkT6T8qqV4fHIBjnnb1vA8KfRy-5sbT7vEEgnvCCSpw7VkmllKR2i1PUWVYUyLUKiq-b67K5J3nrn7fXSezW0TeIGuyTGv0Qux-z33d8mBatagym6o7IVamyAZHG_7cO0euH-ejG0z70PEfmh4E4ug_PIoDzWbZ8KEAf80MUTdvSYyGOcy6o-b_bRODIwX7b6s-TJvHqNGbLqtwhnaAvKcm7QJxBpkDwpP0l5MfTrbW9GmQCHav5Z96cpz7fgpfNtDSxDl6BntlEINQf2yf2HuOmCrEWXHlH_Os_VtZELgA2ZH1pUvHI7jb1Ts_CUFW1ShuS23G06MYOwX_lNjlGIfLUjZImaIzuAgVY3TQhbaYBJdplDqP1BsUvfljejQSaVrUhBX8FogeNt22OCZyWZyM0u0SCEsqeuuekojHdnH--JNC_AzzgYeuGbbTg7BE3GwGuIoYhCMHMYI-uCkM5vVdNdBtulwIqhyUYBKqaXxnEfqV5FfzHAQULsx3nV7OiOUO7zJbtp1S0rKlIJAsAIxwJTwex_jimgGc3-OWHm5imAzBivVJk_l1tX8ZavxpOHr125m1VlFu5q-LsLITOY8ojP32eLkDKbTp1A7Gh_6FLnwQ7Jsitssaeh3siR8GvyuPKG_xCg_7APcojYKGbGcXRxrnQIjdjLUCLp_FzEdDdDlMjFcKY7xU_YdSxRnasm8sgym4b5Zwc_1Snyj4_fka7rRKQT68THg5TFiSeNgpfQYOTsMf5MpyIZCe4-hewAyDGfKd_-zrrO5ggtmrth5rB19LnykRVLB3NWtxmzeJTBrFiOZxZD-6C5AychbBtfoMaLHxOKjv9ZN7Nf1TGMWNkAx6xgie1IsLq9bj_D7Rhzdb9p0kH75fyTjHLJKnLLnonSd_ciiYyLyetvpjN_z42XeQxfAakPgbHBQOJhPmD9oIJ1y0Utwb7thpxLLypawGFtSOsnAzSH_AERWSNsBw7eA2ahBGc24_bG5-u1OjUCSz2XBUukBatOPsCfk_8RAw2FSDMgKjPddxnhnJAumUlIJL8bOPP_yxT9lOj0q_qgDeiD5v3ZUn_Hcxwz-k-SLcitqp3-pXKQPvo28BJIiqKYIhnOBV0bdYXmwcvsRNlOc0cggYx_FHnfVjfXDdqa9YQ3ZkyZwXN9qIB81c_eZDc2kossrilIC5jyqxCK91wjciJ88MwButPaAvhlbJNXigURuk3Sfm6mBAGB4GohDOQwdVSYVvVMkS9fwqX7jhpF-Xpf2XZWds7X3iLXikfM9415Vd0wZNLeFq-YAxcqnWjFhxxPQLJAkK0rfDAKCZbClIn0G7DyI8Y66Mrj9nKDnsaGSKfMyWYFYJUCd-ZOiemKCBVJviCdDwwy9H1COIzrdrycze5eZ2HgVQmesS8kXgkTzJgzTz-xGNLAp1xrJFlvPp67dBnHA31gMsnCrurydwwjvG6KdkvaS-HIgCBpD__TiFk7hqH1nuQSvQKGYuwaNlGyWj2v9wp6mGCQ9LZ15sM3Id2VvPieZJs1COTZYUx4V3CKyHFEixjYrJu8N047I53YaXkgGUsQ9EuI2CTTuA8pWPEqL4KdqxKeCNbvlP28RuzP9ERtEkYIthGCTBNqsg0jzT5s9e0QasAT88494sP_pcTFFhcN6Aw33FqmSxMM9NN4hKZ7Clq3sl55yaESGAxg45yD3NogpTJ3mxthCQaPX2dpSUXKGpKq1wVDAAABXlHxmxwpndJRyIfeIx3N-L0CW52Smd3nggP3xbKDipGjAsCJut4CutwZumBNXiJU8qjn_Xs7B8F2b1Rj8ovQLP1TUnaHDliVKHziTPxWBgUJq5f0CexemrbMNl-yg_YXhfC-TBqz5RoXuZuVGcBq7XbRB-7pA_AVGWWk0Dn2oodEkoWVHPA7nFMTT67B05o6azafdGCTl9QGDi5kCprLPC8XQqDQ20vaMBeAR18k6PizsBIM5UNCY00roiXgz93EyVsx10sBpkWBmHlkq_RiLUbObN5TZpNjm2GpR9GkZZL0WRshBYcwpPY5sXGmey3RlfBtIoiD4F2tfGmR0l40CQrHoM_L9UYoxIRqVn2UMqqd5iRJ2OE_WcpOcdj4Gtgbou3oWqpysgjEU_L2CIZLjMKRevu-ctX0HbJ-EFnlV5UVx_kgXJ9amDvcWguDRmSz0nWOI9QoPpdwRFsA27ZV9QanTiloxGncrt1-I4IwFKSTT3pAUfl1pXc-kQxDru2GHDwPcgZyLfhgWcvb1SlEt56XKQedcabFwJZcchKt_lZOspNsYyC7mPC-2_3Rr9ykfaUbNgpxgqPDCjOxXoCNw2oPxzCbyhBFNbYumu4ibsH8cJuusJEgr2CypHfmZ51ZCH_rdSDXoqYsjJWIqSyD13Ud7rW-mdE3jlV6ZxwDrIaLjkHynZZDeTS6nqNgHc-oMEiMFhdijKz5LBBfbcIqNnPh-Z00IlbcI_6HgK-RHRI4oX2-1J6QiDjglQnzrbg3MniLXs43HEE4xQqfD-JVxxpVc6gxce8mjq8mhREXak0o_DEEQShIL_OuM0uVFy4Vlk1KalAnc1y5XTXlW30BSRz3gMjqE-X8EkZklB9EgCzyYb5O3_-xEjFuIcrvS5MdP2E7e5IQuXNmzO-uloOa5jGyfPAvZeKrsdtrZGjTZdRG11kpTZkirsSgXSr26S0beZECT8jU85t3KEUGxYSW9fU0nRS3BKWO5UgfZROYLxvP1ufZZCCGVjWHk4V5q8lwHPpA6ouXpFAN40k8FyO3lpGgJeavRRnnvwVzc3zvKypeBOj4BVws0cukzWXLEVYP7QvBXV0jF7GTCdGEA93Brem1LxKACGg-fx8rJP-QJjIdCaJxuhAc8C599pfos9A6LVodJ5xcN3pGlvaZWVRpbwNQagZv-1pkTH1ycbGW1tppTrxutjQ8Cis3BbOA4e16xSiyt-wJ8NyoJwM3sjtmYK5qpmp22JYJxTPUzFiS-0TOLP3TyMJlWFXmq02gXn1PMsEGorTu5W0Up2BGWGreKQwIFc4q5Wyybm1k8_yhahzFTtJEYNGmfaSP9yByZhGt0D5TRie2eHMBYKPUb0nIknRgzW2SF3_Il38tDockvV5RNxCpVW7B1MzylOvGCyU6shd5hnWFnWtxjkZzPuqRQ1D38siaVhSpaFL5DLWwyne1vEZloaoJo8w4DxsR938dxIaC8GUug9oNblS9BrekCjE7v9tSJypuTSuftsSg6v9G6Qq7a9aKCYNYfaXSDsZ-K_YZM9-hmmKDAlK-nzUSRRHH3WaZEj7Bz-nprx5GLMap3xOKpBtzwld6t447k_75VuTc94MK2Cl48hRaaH_8KmY56bWXEuSWvAW0Uqdq5I80799JloNBDuyuoii5tQzoul-W7aKFLcqWOqjSbS6BfE0R2wSvgTix778WixIPo5Ke9oaHa293eSx-3MLfDtsxcO_8qbY6l5NlqNKyJHtq3qApSEN_nUzqo2t9fP3c3-62RjlhPIoD5sAjQRaGuMvyTDn0jZ4-M1MtwogxyUL_PBmnbPWkZ4iD9jrj24Ta5x7q1MXnT9iQsaC4ZCT04EkQTLmnT40-wm6sCRCOhStqALijJfp-G93k3737NX7bu-2SO6jHTEO40f-YJXzdjUUIsHY-WBc78vCncQ6EpZQzN0l3MG2sJaRhAWMPu2yQysLAIqOaQgdy4lS_43eJmTJHP_fXMk7DQO7kc7XDfC",
            "text": "Thank you for your question. It's an important and complex area of research. To provide you with the most relevant and accurate information, I need to clarify a few points, as \"breast cancer\" is a very broad term and treatments are often highly specific.\n\nCould you please specify:\n\n1.  **Which subtype of breast cancer are you interested in?** For example, are you focused on ER-positive, HER2-positive, or triple-negative breast cancer?\n2.  **What is your goal regarding \"synergetic\" drugs?** Are you looking for officially approved combination therapies, or are you interested in exploring potential drug combinations based on their biological targets and pathways?\n3.  **How do you define \"safe\"?** Are you looking for drugs with a low overall side-effect profile, or are you concerned about specific types of toxicity?\n\nOnce I have this information, I can design a precise workflow to answer your question."
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 197,
        "promptTokenCount": 1456,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 1456
          }
        ],
        "thoughtsTokenCount": 1259,
        "totalTokenCount": 2912
      },
      "invocationId": "e-e939c97b-38f1-4af0-9d7e-2fd9a872743e",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "3c6f9898-a140-4c5b-929f-cbae51dd9e50",
      "timestamp": 1761138880.615789
    },
    {
      "content": {
        "parts": [
          {
            "text": "The drugs should target a combination of one or multiple genes and i'm worried about the genes safety. "
          }
        ],
        "role": "user"
      },
      "invocationId": "e-c3084213-7cd8-4068-97ed-0dcceaae8fff",
      "author": "user",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "df118e20-f997-424a-996c-cefcacb7595d",
      "timestamp": 1761139155.137318
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CrcUAdHtim8VRY99hkEPWPQurncHbzUXcFFUDjz4rdQCvZ5GOr8A7PDIqP0todb-uZprsrz_zUQWgGyhmWu7Di5rmN4PsYs_AnZJuKdeE5W0jtrQ1acl2jXBN03JKYCjieXWpRpTH3VDGwuPfDPSzDWJlE02kwpesgbG2iSaeCbhi7VH4qrHwugfOrAQFcH4apEq3bIrcYMhNSxxa4LNioAyID70vNciZ9w9T6WFReTSNAPuxMePOBRoCSN-b2uLWMDrEGd5J8Gn29VUx61hXJGZN5LnUOPT0nsqXqDj6kka4M3u6Heyoet5BFf2nxNOoe5vMXvSLtxXtlNtOIsYF7EemY5GF2IMHhU9RbAUolBfdteQfxQBG4Cvv1A4U8_8wTJe9ADAJGpGqfGAv4lwSirVYw7b-8kyjum5ru35kE7XCetGAC8aGQPx-VO81yt9JmT5qDcmWdt_hK5p0XdHKdCRCWE87wUwlRd7qxvTG5dd9iNxTGSb71xJIOyKG0d7uAEPeGMW4Q44Gh3TkbV7ML222g3db9qC5l3wXZUhpjPto0f0Qo1yepf-z7ALXj_syrWzdjyAJRSq9B_iJTmEPY-4iii7FKerFAyl00EUhNKVsxnpEO6GMqlbBfYxuJ-MPppKFkHjTGv1CtVPpXuh8BAhlYkEU8kIBkQ_0b_3w91bKcMIT-Bps1YadpBvbi3MnOl8cZKrdGHZS7xFj5eujOxgsh57wr2gaBju3qJnKATWzpsAWGp50d_xXPRWbAG7wOOREZwHtU-V7V7ssYxcF-zQZbEWviRThKG-cPruA0OXhJ5BFEbDubMUHbhPFtQpvLQiMz5VEXLZ4baovZ6HVCzxNzN5xZS9LcJSfz_i3F379Oojq0etA90PzN1NIb9HJ_Gv-lU4K88FMZ0zuRCrR52QFVcyTeBVNQDh0ZNEVZBa2e-eE8KTbp4zKVEA4N5-Z8PSInDrtEib0A5-nExuMMCJA8reIdPNjeb7-IVl_03tLGv6eiVp5DVtNbFpGciFiWGBiXxWZfaFHGR-JQ-OyHghNJkBfxXABRWFVs54zZ0wDIJSoslsUNOmn7HDxu5C05Nr9ZMrQe0K4h_nED69tpZT9mvn0GkU75W9ALGjQQ0bHkVUR8D9oSR-Uvt6iUxV4iep38FsX7QXhUGTqStIvVEnQrfKKXF2mhdptFdBMrxZKq1AIWeIon6lT1EHlYXyFM24Iyw-tcntk7Q7Dmn3vVzs1iLSbFLM7dW6D0Bv9t8SGhpQMQ0eekcVA7OZ0SaopcVfXEhKoUW6w8if7R10PIj5LRms95VaAq6YW9TXgpPNyzsTUnLKJVhHHxIh0SgUo5TiXnVLs6efyI5bAfE4eP3ga1MvjwOz0UBhBPEGVjxQYRL9WfnTbMjpEXEEH62tyHPypPIWE5vS9vHefHKovYiWpXBtMHDFOZXE2zRfQFbPEley5genELnQCDPgaFcEJuKYbSmXWsrSjXxmBaNjQVyMEApAelbz_Eg0na02eVAVxIQOrkAIIbMHOpmQBniD170T5s7SR6Oa-sQ4n02NGvKvlS4Kkvf3LGL2w6zSDXDcKNAE2YNGq52CXYGYcMDukS8zH0UTElKvv1yg_DJTGjYf0Flgat3JnHRMCz4nfOM3gonsAQpBnN6H04jQ3B7bQrzR0NmXZ1GgYZWlV7jCX4-mlob6FSgEqpyK2keMnGXD7J3Tiy8CuYP2Ziuo5es6jethLXYni_NL53I1lu8C1r7Snf7063eM9dDANUah-GxB4PpuwUB1Vm7XMTU26VfD1UMSgHKaBgsVkLXsJxmB-_gtytxfwy2jX5fkkZuBm0wtrgfPE5XzFDrysUv3oqYl249vijFDSIUBgXrFCVymRXlo8Uxu3Um4v106AiojEpk3r63_UQSXwf-eiD1wUG3xcbpuFfhQyDwv4rsTLbJsKDuJHLA2bdpI7gt-8U9XdAucursGJM2Yrzq2eumQN26-kM7Wht8OEzSK0rEiX2TskbZspjSRGLlSjgGiRFH2dd3BUoMp6fFg1oscoe2GW5zXY81ljvjX6UtYWp5szJi4NaXR1q3ckm54Udcm6AMZNST6ZWchp2nhU2ynOWpHfoL2hTNFSdZpANwCZ8uekXM8F9Jh5Da9A8lIS5q_J01vw5mxw0YI1TGnjtHgyiwF2fDAKtbN1clz_IHgVemXiyDxVcbN51wOvFNnykcm_0HFWRXUxxCuWUwV7lfZGRWAXEpj_jSx6ETejsxy0TTClT1HMLL64h6dfLT7o6RqIbsjrwBjfTjDnAwaAY0saIuOQcbpM3mxo-QpIz7tIGPviHqDSsnCvUTS3Ferx4AV6MuYhVbLweeP-fUNt2sxsakJ7O9Xo_vHgBJgPaHwZPdPljkLqLZkEjjpSgczCaze4P6TxPADB0QiaumcIQyne3Gx5GeuKB2nMYJcLtKc097ITCJhr1C9pXml6Sho61LoZNt6EZujLFFFRuLUX2NQpGK8s9x3FVO3m33AK3IAATIpWrKRmE8G4iFCSY8i0nBwykHRwYmBVscf9oGeO2zPEgs0epAkizvwv1lhYq4tRuwKOL6M2EbjBicT-ZW9cnfajb3fUarDxPcdasxHJWPuGr0DGWIOWTna_ouPbUy90XGFDV098wR-F_tXm5E0z0ZYwZT8UfB7nyCIP9SU8Oc2qazKseNEgUbwuZJB-ogieAfBHVGpPx14QM2fQ2LcOy5iII0BdQXBvOSqpAsc7dQ82Lb9NmbD5pmDipclbl4zNKnnm6vWuTnZRFppdcK6vq7DGKoTkHgnjbMWuMqec51ioanqEaJWH6-iuuTotCFMfnb4nsrG-IzPVchwLATCZlmSsKeUZwLAQKza-B0q0s2c0e6uHy02Xh_9TuJoYF_H46PXxaJosc-VoiHbuwzkWjfn2r_zO9xE83tBaQELN9rTPrJnTTEzEV84Y55iisqaGZNoFZbScwT1Kxh9zf8_f3cbHUtIjY4m0SmSNWO12q6dTUFFYaPFrJ-aRBnu0VorapEdB0ScyQ48xg1w8bdTorUqi1u0QSbfq5-ZtoDcOeSbawyxErOYmz51lfr2gvAm5CcOiK0VeZht4zjMtMU1L-g626l-NNq00sHme5rw9jf6nqU1DdV25jC-yifD78bxZeYEIn_dvP1YYRSOSfJ1eX6j-qC1_O3dcDVbPAh4Ux3ORbwqzlyuN5zZLPMZYp7c5i1PyCWMAbIACNvNBSbzFsfKu-rNN358oGDqtYYOrW82bmkoFUxeoO8-zJIPolfZd-T46NVlG1uAFYnY48o6kVa23ljZ2yOT3Qq8c8-949B0-w97Wcqrqr0Gxfp8-NOlEguXnTYc4pbULbBwq8_1mA0zlkQ282ozWN_Gl-2i8XEQCbizksngMqpgDVCEQRmslUhVPlR1T2r40Cz0fnnyceha_qAIvrazdO1uUgHhWGmq8c0RUJXzjHjP57T1HZSvDkBdknKEYviYLbofjE2cTd0=",
            "text": "Excellent clarification. Understanding the safety profile of the target genes is a critical step in evaluating a therapeutic strategy.\n\nHowever, to identify the most relevant genes and potential drug combinations, we still need to narrow down the context from \"breast cancer\" in general to a more specific subtype. Different subtypes of breast cancer are driven by different genetic and molecular pathways, so the optimal gene targets will vary significantly.\n\nFor example, are you interested in:\n\n*   **ER-positive breast cancer?** (associated with ESR1 gene)\n*   **HER2-positive breast cancer?** (associated with ERBB2 gene)\n*   **Triple-negative breast cancer?** (often associated with BRCA1/2 mutations and other markers)\n\nOnce you specify the subtype, I can propose a workflow that would look something like this:\n\n1.  Identify the key genetic drivers and dependencies for that specific subtype.\n2.  Find approved or investigational drugs that modulate these targets.\n3.  Investigate the known safety risks and liabilities associated with targeting those specific genes.\n\nWhich subtype of breast cancer should we focus on?"
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 230,
        "promptTokenCount": 1677,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 1677
          }
        ],
        "thoughtsTokenCount": 541,
        "totalTokenCount": 2448
      },
      "invocationId": "e-c3084213-7cd8-4068-97ed-0dcceaae8fff",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "0f9fab83-5e42-413b-b66d-b153d922e548",
      "timestamp": 1761139155.138449
    },
    {
      "content": {
        "parts": [
          {
            "text": "ER-positive breast cancer?"
          }
        ],
        "role": "user"
      },
      "invocationId": "e-f853bdb1-a4f9-4451-916a-e35451e283aa",
      "author": "user",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "3f9a4ba5-3bf0-4b6f-8c0e-910f5e568b76",
      "timestamp": 1761139176.118982
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CuomAdHtim-N-eD0eKRqPyWaLohWky9orwCGr4REVP4WsaesMuez7QLJn_nCnB8EEkN7WCfU_fesk5cPtXl4fjwIHUb2wF41hv-xmGN02RBpGQng2SEHVzgaoBADc-np09MtiOGpPmsKNMl-IwZY5iJvOL-q6AkGyA7AUp2tl7II5GeCYUrN6iLz1cmm5kYAp5e8NIdV5J9qlZzKd9wAxfdPk9p743NUjPaCy6rRmW3JznbEQljHot8EGiwDngsemEhDmNcBx4PdiuS0o-qV_V7HtphXL_WJCJocR_liULJZG7rmKFHJNeN_azmn2SXYv7T1YjRMrs5c6WLzEpyXnAHfP8fhLXVB_T9zT0KQj0wWfJ4S1VZsIN_hz6u3COC4cOoEmCliumeoAYfKaxjNT_Y9OMF29OARXHMK6D6MC8sUXjEeOozwsSB-Hy3w_YrOicoJ5ZtISLq-gIY4pVVqGhKkAD2TYZFU5qRfsJyZ_WsmD-DwfAXFzHgZhuQ7Gvma-1xgZoZiOYVc9-4DopfmkyXU4fWNNPpDZTEQIdSrDIhBUSgk5tS5JWIkhQ-jfsC15aPCBbfqkz0WJKl52DCd9Az7AePSJke6ppQ_NcKFZc7Pb42Ky1SNfS3XQRqf1Yx1xS4714gV7L0BPknhQJYc-2Njx09Wl88bNFyiMFw1tTWoute4fsZDlExWyiQInHQEUmWfF7Byao2BU9bZd9nBwwXSTjiTwiLehJlF2LBDZD1EhDoOzUz-95pU43Ll5x66T8Wij-g-v7G5h8XPqpSE4vE_kBHI6Lz_UivmvqElXTGUUW6_vLhzcGQi5ItjuAzieyfcazfg7Z6eMULp_AZsd1Q8vqNALhxx4JcGEOySEyZNO7_EODCF6PlQlCWyIyRjcuAJ2SUR0NIhNyt9llHHzn-19kB2fjNeoEn_SZ47gPyOXT8HNnaDoUmrHxZP-A4B9vJi6Jrum78rC4ScEHICIf1486CHlft1UXJEiXjAcBPcQ_0I5oR6Z1EOrjOcmsz5sbvE5oWmEY2vDtPCdajicZe9rPQNy-jlvK_kMEJeVhcX9pTYprSmvjHVUAQJCSaKGj2vaM6iJ6y59lFKT08Scz39i-6BHoBMzrfEfwj1jcMJx7FQq3iUhntX7x7oN2RtTm5-fuIxlWXzYYCEr8FQW6NBdfMffmXPQPAOmT02mkuuOxJ3_vptn6o9n2VWq8St-KqWbBUEQ1FUJVIS3J_hRU7FzPxmZHOF1PiS0-JYg1Em5bzkyqDmhePWdPxZPCwJTjCfXNm2vIirdrUYpD7kf3EQdAUpjEvaDngcaMprPo2aNkWYSW-lfvlGoSOiWxX7StQZx2cE0QFZjkEvxUhbnxLyofbr24MZP6KEbUfr3lXw3rXFaRiO8ltz4FFnTAaw3J0nxheVXr21nhym_53qROROXTDH4wlCO_7Srw-Njx1E1WxGqS5IGpli9FfLKA_YoW_6FaRjOA1KbQ4jsBY65yIRW4IqR_aUj2bjIPY7E0CclTzH6GS2XdehvAAJ2sHAfMWepmFD7nIdTj_v9dvQ2iKY9Sg1rP3NrlJECCsewuKtcDd7PLAl-r7yuI5jo9132kCVzBCd7oMt9WCZxGPjdCaXujMc8D7wYYqFdz9Q8PoMPSbMK7l3oUBFrZJPqEaSclMHP2f2rlcVYC7P67DaZqoBuRmoWa7BVyr90s9ID-5gz-uBD0CKs5ugfls_rS9KSjP19lyXUAKOMZUT_aQHMG0veB-zfeDZRxdseuL8kt-6sglPmJa4ZSwZMGPQfDRz_oT_4VaqlVkbvUdiqesy89Wgiy078bh_Jt_TmMw8xOL12O6E7BQ6OShiNVtX5iLuYnNRkMDvls4N0glrp4vUl_oSmPlZQzgTXcW7u-4Ayul7MZY4-y01g0xO6ovvcSJ_xkqfGr4CY2jGuIZPB0fjq_Bax4EwtgHMRT41Mc9JjZLTw8IHDPX_YiPTP7vHrA1Arh48n8ED8nHz4DWHbUxm-CtlEu9uNVAY3bp2fumRmxDZjUaTcqbVxPCIQ4q3lNfjUwh9bnPFKXG7foiVMT6bOCxYMmAeq5GmF-Ezox1pn62EkNuJMCbqnNy3kDNeJeHdKePTBaxgVFhULCzJ6LSVWrrS2j-sUHP9UNYCJfqQYryyZtJw0Gqc92V21RpORKedwCBX4GFneT7P81p-3xFzE4YvuTqwW2-U06wLo4Rm3T35b1OD9I3b6O8VVtPqeVt0ECLtnbM_c1dzHkLE10F9KWFO9mHkjOkXp2i9BywPLcl0wBW1azb9ylTAKkbNmynGcgTzZQN8U3J0boY1hG9pJeBMEx6myUM6NYIFiM3aJZY6UT7NboNpmWMmCSu9un2flxEThfsZgzR4jiBeTLEYUdLjomnQTNm14hXrlIVdi2bRU7Tp1LhDC5xy3we74EVIpn2bV93D9FnmTLNK6dFtglxUzQeDF01KwvAZUqtUc6TUnflEtju6WGDqg41MXuikTp4sXHh_yNKKdCflCg2w5fmm_X_pJBWrsvzVogtDl22q-LoaeipmTWE6tVqxP0mEiokAqgjil_ANza5I7WR_cCUZ8ot1WJO93FiLxhvNtLAr3PhHWSwKIf2LIXCjkWEGFAITPcqKt0sacWVNhjJua97wUBiyK_3F61hy0dVrm3_aVCDy6LPmO0KrXLxpax4d81QbXk_Cfzuewr0aHflGg63TtSZjKiAmuzWZp8F2wiwIy-zydAG7Yp5_a7UvxoHZDxblh9997c9h8ibldvPsR7tdosubO9XmAIcC5iiJvvdl9MQeORViQxmn6Hyd5c80LwqjHkpyDyl1n_ZC6H_P2gRnIYiGuwVbMVU_-QJMGkR397LWucufCYWuLn9C0DS1Mfebw5gwuq2S36_xZAU7j5BGnFn41OLCOYANcG8DIEFHm5kTG1TRcInTgffbGsaaISB8rL_W8UfwG5aOyvptnmfEUoC5x00toWR0Xc-htSwMsdnh4UeqSA5HvUFza6OrsmreyZBZVtcGHXWYsjprjQGZX8qYdds8uQHEEpgiYGlTQGYSb95sk7VJ0XBWxMTt3rP5sCja7B-pmZTMgIJmVjY6ixhaql38dUB0jj4kTn54Plgg0U4cZkM25IDCtGEbIBE-I_UwcUAL6mPNE3TAJOaFj_IgSOvVCL5wbZi57wm_qOPB44EARHzv29zR6G97TZP_0DK3iqDgYBwhjEsfnWYw8Sn5vpdmNAHtOPz4bBShQMB22GviXg6hnh0SwfcGca7l3ZxQZKS9NfefMukhACknkvgajIO1jYYS-fsvVIfa8qShmyoFiqufi4e8EfOHObk7GGG01XY36K2CErUBO9OluK9nfWaKjqg99bJTvV1PBlJzsN7O6cWsK8fVshpPO1FZSnh0RniNCSBdHQkgyO_XIvuGHfzOpTOkZXzCeIK9Dn0X358TSu7rJwEaHjHMcqwLYGpYDgT-BL0rnCLyNoin5OooPTSpstOvt_1w5WR4J47ZhBGSYTPtLYX6q_ZKr8OYiiPnqpYGLKF-2yg4qAEBfAf6BISexm06og7FfqKincSMrmMUAVarRhDRrley1jZTHGNBBstomrMIYzbJH_jkufYiODebZqoPzloAmJWa9ix8X8eKTHaUbXWUwwBpEBpXmgdKtqVJzrLeD3FQamSENnkW3tlGj2nTKC-FeRTpnDocrQglsp4FsFRTX5gu1OR2yL3A2uXiRdp41dHkoS21J56BJrwl8ffnXX3LazfybV7X9UVuVPnUQDvJSgDi1K4fGesh_VTlzTN9p6c9-tJJJ-knQSdlzsGYoYo2Yw3A2k2dSvBt8lBt2wxaC0gePCJNjLN7BsxZS-pBtC-LPD8AF5-IEJkcPwffJ0UNrfIB14nOz0o978u0g04MG_jc-2fG0rdKkSMQyZr3W0fQNP2BElVZUKVo0SZLdN-pf-Sj1PW8YOfk77oZ6UvadI3wvTS3ve0Cs5YC7XBtCJYrr-pfenAnshg43VHM7cSSVYFrgbrgRMmKD1RSMLsM7UNxhExapietJCC2x6C73HR_UfXjGS5XceDV2f2XViX6YoerW0ZurN7Uv86eiVNgVMihUBnJ9phy2OJKvBz5j5uhE9gZGtbUru-qzFBwAKkKoQMV543YETmIO4TeOLsbBoy-9P0rGtbDSQXrxr3gRDAdwDD4Gfu6_0B2BX0AoT3XmOUa7PYse4X83nJ_RrXYO0ldi0Zga9KSjUctit-G4cqXcrKFwbunI1YzP5duAv9eyZGklVhy87nzq_TRn4gUTOQKakjCr9ZL29FAxSfBjduI7Xm1NUrR64-EiVXEKA_XE2PBcLDz6-m6wcll-R9df2h6P0b1U1rM4FWsAdcPnDdPT4EHUxcLu5LZ3V5YIl6QXKbh2ouIUkMvLTfNKZ46jF-5BRkEZOWufvlC3vjdPSpFNBF89ShgBKdBorYVPhOL_b2KhSSq92ykfTu8rjIZOd0oOIlznjTEMC4YsOOPDIDnRsmEEULy2jEWBgHA9opB1mz8DQcmSLlvPQhNDcgoCd4rkv7RfZ45aLbOns32aORt2edWGAR_67yahVpET4-ynAeSyjcZMjsS9gdvRTOLVy26-00OhtwJckfv9O5IO41L1iRt4E_DzSh1xJR2lPuEK00dqXsH7PhGkQKcb7iukoC1ycAR1CMsDlz0HbPR02XE_P8Rasy9tJ_X77Eb55DQlDqEdjx4Xm3uFWVS2OnWBIZzoLFWoI0uE6OYAtfv74GukXZ4oOvEpIj5cs17FpsUPfyt9coFL7arbOXlUN1eJ-mty9p0O6xbxXLMNFgXlZ_A9qG40MBO1VLPeraxZKHASMBUbSg-sFufZ-QP0jSXt7eNcr95HyGjUs7WkrdONQeCeMn1UPyxXPV9lcYx4p51xodx8kxqVgJfEESOsB992-_NHz1rKljhPx61d8Sjj5D2Zcyyqnz3npOffnEIbOCVwzrFTsf6DvR4nhWM-S2GFzpF9tGX5LuxJGzANdA6EgyAkkEezoL1DpawrEiDapUDpWfvtSaZSnZI3hbShOT1myCdJz0ZIlZDzK-kvKmVhtXc-OqWvAK-hOE9wiguKeTK2pGJTWQMOxQzdmIPC5IwMpV8oHLr_N0go6TicigmQdwMhQTYuMMIRR1niskNPVYAPW4MMOHMPtKejRt5UL_UbYCkEwbaDJKigg_Ry3q8f9BlhLNQ9ox7ySNEy7noTG2EbNkKTqt_o-O42DvpfAmKz0FU4skwRuwm3DOORjLjzKB3DdZkpiI-fsyyAsUAHS_MP4qxDiRERnhCw8U-5g-oTJ6tBn9MAyVIhXwn7IZWcIVJdQ23dDOjbxwcdL3mAwK1aM3KOrf2cnmulyaLRUXPyMqvDhJt533iTnZEdn1REc-AVBhFUM0O6zgCaAVAftmUi5IunoNo0WahfSlXUlTDLVWJTUiXpK0o7SOaB-gNvJVY-S5dANQTGOcZC6LmBT2ykqsbDLVxdipfdNuUuzRMdwz6zS3eBOylSIb6wGjkpnUl_9ljHzUYN04aYqaqZZCSn7gR-goAlBSsK9J8PmZ17voXn0Zhs9orHSA_JhE1KTvYt6vX-WuNbHZW8yQA0NqvQTEO047IsV7gnWIZZLo74T3DFlC4MsKGfxIz-ATv_7qCiGMCUMqG-XIIcUNMTr9XC2kMj_6z7feMFhLImaeLfl8iM2-33cYTAsUR2Vjpcu7cO4nuUmQrehx_1VojsKFkE2qQknVQl40Mse8tORDNpAFaZTxr6TT87wpffViKBjGLjfqrMn_s0SuLuB4KFyBRWjkBuWzf0-tFhCP68jbQ1JObTKFr7Wq7mfPlM9ukVzhdZbGOPZzkkW994kooICw8Fy7m1y_52JYUD3UAZfpoue_iTPOGvUij4ulfdzlLwLrGVPvx3M_sIEE2Hfv9gFJnLnBerI9psZEPG1wCgg_Pvua2JbAXclN0b6ECJ21iyoutzBGZv9OOvDfO90Z6au4clNOZOTsoJVG6wZy-8C8lFmFWII8ghprcN0Z832Tk5LxzCPHGfUnBrta96YgJqR_xaJd2lfoJgDeuwQkBy1p-GO5UGjTONen9qr7ovCmZW6LosIAelJbXAz0zIhE4OmQV077m3RKvCXBbHDCEUF_ZvYmljgY-zkpIotT_piq2PgsNH_F3qjVQhlnU59i85xW2KWugSyRiQXoZ1yiIEJxK3J3phGFpTQWlOculr5Fb1LtzHpsKzl3VTktmmMVs4cSGIQKM7VUvxnsQiow1XnFiGEO5XO5pTRPTNJl_Kjkg2EmbKHONWVLk7iJsKmeWglKZU31iiTKpUaNyg4SXtC5leOkB7zo7111KnwUqwF1exrOMavc43q4vQRVUxRQLiK-E_6AJsCqd87WBFd7GNhUzTDnPn9fMrz8X5aRp55XDCCey9Oex1tCOVKHEnlS9u83LUIX93cfX4S_gy1_PeKxKmoOVQaNLgCzCYqA_0E0MMXQ8nOhB3nGh8pLzc2vwayUtVSy0JwUXafqtrbxJLGfcMpj3AXrY8up2hHstTC3p6fmT1wzumrHy_8xxmOQq8oTZg_DI4CPmGGRlOX6HPkDkoAvpdh17ztyK1xq3wLV85olRjig2prlX2fQryuyPF-0=",
            "text": "Excellent. Focusing on ER-positive breast cancer allows us to create a precise and actionable plan. Thank you for clarifying.\n\nHere is my proposal for how we can approach your question.\n\n### **1. Clarified Question**\n\n> Identify key gene targets associated with ER-positive breast cancer, find drugs that modulate them, and assess the known safety liabilities of targeting these genes to highlight potential combination therapy strategies.\n\n### **2. Context & Assumptions**\n\n*   **Disease Focus:** We will specifically investigate Estrogen Receptor-Positive (ER-positive) breast cancer.\n*   **Primary Targets:** Our analysis will begin with the most established target, the Estrogen Receptor 1 (ESR1), and then expand to other key genes implicated in the disease's progression and resistance pathways (e.g., CDK4/6, PIK3CA).\n*   **Inferred Synergy:** We will approach the concept of \"synergy\" by identifying drugs that act on distinct but complementary biological pathways known to be crucial in ER-positive breast cancer. For example, combining a drug that directly targets the estrogen receptor with one that inhibits cell cycle progression.\n*   **Safety Assessment:** The safety analysis will focus on the genetic targets themselves, using data on known adverse effects, tolerance to genetic knockout, and off-target effects as documented in the Open Targets Platform.\n\n### **3. Proposed Workflow & Delegation Plan**\n\n*   **Step 1 (Data Steward Agent):** Find the official disease ID for \"ER-positive breast cancer\" and retrieve the top-associated gene targets from the Open Targets Platform.\n*   **Step 2 (Data Steward Agent):** For the highest-priority targets (e.g., ESR1 and key pathway genes like CDK4, CDK6), retrieve the list of known drugs that modulate them.\n*   **Step 3 (Safety Agent):** For this same set of key gene targets, retrieve and summarize their safety profiles, including known toxicities and potential risks associated with their inhibition.\n*   **Step 4 (Biology Agent):** Analyze the biological roles of the identified targets to explain the scientific rationale for why combining drugs against them could be a synergistic strategy for treating ER-positive breast cancer.\n*   **Step 5 (Principal Investigator):** Integrate all the retrieved information on targets, drugs, safety profiles, and biological rationale to provide a coherent summary and answer your question.\n\n### **4. Expected Outputs**\n\nA successful outcome will be a report that includes:\n*   A list of the primary gene targets for ER-positive breast cancer.\n*   A corresponding list of drugs for these targets, including their phase of development.\n*   A clear summary of the safety risks associated with modulating each gene target.\n*   A science-backed rationale for potential combination therapies.\n\nShall we begin?"
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 588,
        "promptTokenCount": 1915,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 1915
          }
        ],
        "thoughtsTokenCount": 1101,
        "totalTokenCount": 3604
      },
      "invocationId": "e-f853bdb1-a4f9-4451-916a-e35451e283aa",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "3e051a90-82d4-432b-96fb-8c62662c1c60",
      "timestamp": 1761139176.1201
    },
    {
      "content": {
        "parts": [
          {
            "text": "yes"
          }
        ],
        "role": "user"
      },
      "invocationId": "e-d32a23c6-3af5-46ae-9059-91cca3dfe9ce",
      "author": "user",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "8be17be0-3547-4473-9fbb-895de19ecbf0",
      "timestamp": 1761139227.284655
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CqEDAdHtim9-X2IsKvtnBjSromgdqP7-U42vPjobHzi_kLyCr1oS9PnZ6aYP-c3CrP3ME4NbKkPpfNJczZWjJlTja28d_0zf2tdDBHS3QG-EMctdgQOx6IiMAFNgjpeaVQ0jfxOUHts_fm6AV-j8b2J6J2R3QUKX8HcfTsAVHalUC_jZL0oF4Sz8wRIbTkFPC1qaByV2-OMC5O3SEywkfZud84dgmNJYcAiIMWvJtOykKL0svGmapAnMDZwoZY7ot_MKL68tyby6u-UAmIOopcKincXhDCD2MUrgR2dS_RtxSBk16a8M_wYOlMAh6qp1oF-JJ13jWiaqOK82Wl63Cuo47CSTNmVD8ZnmIe-oPk353NIvve5I5OInQTmc-0V6nEIsXvsUZB2n1SCBlKCmlG18sjfgKy2-8sZfRUpzA_p8WyRcImXxX57svroqIu7BRG_D_SJsLtAVuqV7aB-61uYy87Fe36t8e3xx64E8HpFUqOScIF9sWRuZQVx76JJ8E7VazPxt0wcgYDs4urMcS3TsqFOAoBBpFDCCmgxp2uxkmKly",
            "text": "Great. Executing Step 1 of our plan.\n\nI will start by identifying the official disease entity for \"ER-positive breast cancer\" to ensure all subsequent queries are precise."
          },
          {
            "functionCall": {
              "id": "adk-9061a3d8-e944-4ce1-bb3c-98e0e1724d24",
              "args": {
                "disease_name": "ER-positive breast cancer"
              },
              "name": "search_disease_by_name"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 62,
        "promptTokenCount": 2506,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 2506
          }
        ],
        "thoughtsTokenCount": 111,
        "totalTokenCount": 2679
      },
      "invocationId": "e-d32a23c6-3af5-46ae-9059-91cca3dfe9ce",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "e0540bf5-ec59-4c71-b4c3-f537e080ad87",
      "timestamp": 1761139227.285631
    },
    {
      "content": {
        "parts": [
          {
            "text": "try again"
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "user",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "e689da51-a539-4746-9702-179546fa788f",
      "timestamp": 1761139259.222911
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CoIEAdHtim9oCpCFkb6k2D5hKAaOdDXU-R-IbujAi7MkSXjbr3eZpDmQxjPAFMSEHGhKvKaf1NjgqlfRd8P-HVhl7V71tKFvCRTCNixcVqr7UfSVs7sOtY7n4QLwkhh3ExEj1kaEE9FvK1fRQSd9kfUJGlKpJWAb6rfqNHiO19c7rJ3IYCS25LUraN9ssEM20kIKcgAtRpyrcurlcW5Fnaa1RiLEb4YSVojkO7xwixtNELgPwPtcQL66_g0n9_SWaESjUgonZIWXIqkKthGOuJslJ4U9VtrrwMfsUX20dMV1fQVDNejXYFBy90Y6S3mZAAaMGdCnNO_PQ5Z3zX3GKtf4pL0mo9sTK-qyj5uU7ZKyhvKfrS62RMRjhIM_yDM0hR8IJ8nK_FmPe58ivDMOby3N_Vf3mtHBy83GojIFlwzdyOue0kPl0-QZxHjNSRmYj4XTD406qPDeqENW8px40EbtKWY62QvVwiliSICm7xnvbhUHTZ41kPe0yLHfk8o1cbmbkmuDYlZ0vUxuacQmgSAFAnie5BFS_iIxpNEHvyAVasuSDd1Q9KHfys0KxgmvPchuC5n4uLEXp9PPjdZi5Qkmbt5IYTtIq4XEWseU6JCrdmKpzlnz3K7_ONRHWqb8zYK2kFRnbqGJT2PDurZrqpBLEFaZdCN86U83_wwseAm7k8ztEg==",
            "text": "My apologies. It seems the initial search term was too specific. Let me broaden the search to \"breast cancer\" to find a suitable general disease ID, which we can then use to find associated targets. It's common for specific subtypes to be classified under the main disease heading in biomedical databases.\n\nExecuting Step 1 again with a revised approach."
          },
          {
            "functionCall": {
              "id": "adk-b53c8918-de33-492e-bb61-b02ddcd35c08",
              "args": {
                "disease_name": "breast cancer"
              },
              "name": "search_disease_by_name"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 93,
        "promptTokenCount": 2572,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 2572
          }
        ],
        "thoughtsTokenCount": 107,
        "totalTokenCount": 2772
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "4356aafd-8d1f-4ea2-a207-cc999fd3423b",
      "timestamp": 1761139259.224348
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-b53c8918-de33-492e-bb61-b02ddcd35c08",
              "name": "search_disease_by_name",
              "response": {
                "result": "MONDO_0007254"
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "c984b8db-bf6f-4efb-898a-0b510e6445ae",
      "timestamp": 1761139263.638382
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CsoSAdHtim8Qf7-MKj6oPRSlA5jIY6yV-pQmPC1N-1b29kGFiRTQv9O0w4Rt0DJ91uHfd3cJE9WMDD-x1XJn1nSx2z5kW3l7ipe9EbSqr_fWbsm7xAxKwCDvIZJ_s5KMBFQphnS3-XNWbVzC8s3fI1o8P98VGddWCef3C2wEvzze8kkIql6b2LfKz7fGAU45C6YKarUWkxv5Qn23S_zS6rSS3Z3F-18Y85ikaWN0UNCCBmY7z_K5evnkVcbhohS8u6TM8VIcPjcKhdL57fWDE7JzuC3nNRWDfvxqFoGIhzAZ4DH8dA5mM0tR2HtfE3nGC1k7wBQD1EgYTQX5y_3OUQILvMuZRQFCZzyNFUcjyuyxLhimLdQ8BkefRvlI70JWx_0zpMF4R6R3_bjqK0dXo9dRZt4aTfGqRJyuaKgD9ODlKsrBUMIwuccqorFyamR4ZuN1KtYBj3LDCvv3PGe3ZiL-1pedhMTRlWjfYrTKfvEwNJwVuoyYlC04lGUWJpYtZ1udGxPKudpxDpsNLM6nyxLTnjAblWeReN8tTUCBPSlypJ7HV7LrVYHId7C6PB_oyj4mXuWh1ibX_sY1vpKEryeb0261iBgw4Vi50OSzCiNMOHeMez9z8wQAEk9Nqsxxvbr1BUnf9ju19DIOgrH8oSzFpBDUJcQ8WpxuKPZ0dXbeh1OzDyHlZbwlrJk-IzocY-5ZeR5v2YJQC0MX9aHR80tf3jldfZFtD3EmwUXPhF353mmTiHn4gsCU6zkDz8WOKs0uJKvucx8W75TZWxzX7BGxzwzLoRIqNnBiVzL_efjeqryvN4rBzqpIrpiTF-21-IVkCkSvED1l0Ru2CQGe8PMeeOAiRak6_QB-O80_W_xmemNPB3VrXk7l0JeR3kShJLnIebDj_djhh-djmU1F-0gA8501vLng5p46NoKFPE8q-3SzRj8Fj1jXQduImsssdZd9FenLtD4HT6hIa-LHJzzOlSHRNSueP26ILgXcG4ND8Ks5gTcXvbYDGtVVC6fkcZcyFmesrGbJeZKBPWAW_WUreZ4UpPb2-INEeVJOuwZPNy2M_LnDmZ9K0SkakVIhlkSXz3Pz6KTsaGhmPG36gkfaPw4LlnM0sCpeOhaBbbVI1MbPsziLNZ6lrgVdl-gWzbp5xTPg9rLZZyIxVhybCfMVW1BcI-EYd0bIeaSLGSEmgh2mtEi2Kr8b8qyvE11HQEva_WRupDJPZq4kd5J804KrQNnTVzqz5q2DC53xpt2PzN2Pyf_MHqEA-bxaSHJDm8B1CHceJGwgtg3bZN8Vn9TJIAY9r2t5xebZLOfr41MlX9IKPkUuLtZav7vy-8JcgKeDHpZv5AuL4eQ8WVVpKvCvPo9wvrVKwiRSQDDFDz_Pfxin_lJDovNbOyIAzl7wpR2zzruOOBnIdh4sG_yKnR9fOaoTImfQpaydnDbaehnzh5VIUu4x74BFLQ15yNY9YNmdedqYIsjtp7JkocQUBuFJ54cwVho12G4Jd69r28MlXum6z82q5ChEjzXcQPTIv4sINbdzXiSDWHYJrBzIIYOfHu0dUDWUmf2Mk-tmhEF3etJ5i7VWKR15oz1ObOExO7hIm0pAQ3tSpot9zl_thyPCW3nmZRbobzMi18IALiApUW7acTS-AH61PiamWDY7_s8rJB47hBdDfmqrjAvRAVpLIGRO-i9-l7o3zP-shT8_Jlcomwi6FAOCY82QftfE16WSIozpNwvODNhLS1evzOwqlHQNnuBzZGBD6EYQdmxqZkDO3d9_Lw3eooOQjd3ZBEjv_oQyfsiMRyntMiuOXd7lH2Voizf271qQ6NkwnfdiCm89Fe37v5Faa9HR4AyeqBVIGNTJfAgJb3OhQiKNkQ7DL4qqW1gPPQ4FK0NpGOQI3COoBBtPmzK0Lji3OC7_qbB1eU-AdkG5L9aWPX0q73pPhvrhL88CY7FdEK-mL285KR4RtkIHUjJolXFywDav3LxGy44hsaUdV4ex9spI16RRtkYQdqPl4mtn-cQsyzi-8YbL-y0e4x3Xew3yy43IyXf44VOXagOm1NUdVU_-8dihmSONpqP-2peU9A6A4NwzOUD-Sx5z6G0NBDukvs_PaFdlfBpfnxJNApfBc14ys_rdr9CkjOYmBuGZ6_Zh06plckj8qvHa0h9rJhOE48KllrJy-_EkYJwVtUzpPwYrWrGv6nFhPht3F1qeaPmZlMaTz1vqwBE0h9QdiZVJgsNy6dIuNoGfjCc54EGe_clEz6Qi2HeRPgLb7hMl7Lzu6AiAA5XrgYC_8laNsa9bektl79PeAODLnj0kKad5kejcY5cJNvEgOfO00RntjgYG9MjnuQ5kFCJVUHezPpo2DCyVsD6ER0b18Sh2Jt8384HsgVh8ooVcqBVy31L6-VC9s4rAMBKKPwYDhcj6qv1O5Kxl6DzwQ8fXzEj3XKWX88KOZgzpYwu_ilc1ObWRnscKmpRoFlEebCvwgxLME3qZfck80sBnNpuA2lkYF2qKgkf3OvGik7wsFkaFcOm_Ai7nhCOyA0y6qL38UDC_kJr-5z6Hv0ortR7NXlB_0uvSdY61ZZ360chzT_xwJUisgeo7eEmb6-dSEfAXVzzkQyt6cpvFunLOl3mgDQ3co93qowxGc8u_g2LoWJFaURq4ktRtqkHCHm80soR3xZ61nSaIWFvYNAIsyqoLmnVzj9q6HYFfqcVDHPW8Pwzl5tIUUbRvlofJ08wYWI7rDnyJqtpV4IjuCOWFieydHB6uiYhIRmuV7hYt38eEU0z9L55vzrumrMcQs8o_dhIHMbaN6MZsUL4oK8yMdNVQAuJdX4QA6NEgWowLNlXN3LHaivK1sjmEVO8UmPpkcaJIyaCdf1xI0t7653G2EdgeY1l5G4_YZwipZuLrGHEHEhcLiSnpLrgfoHWihO3lxDjISPIhOiuaOaE-TW3G6gcLkqCIUDzmn_9_ef3yNjeW285TSyU8nciso_ZHmCBKHuSFdzxe1aX_zQxQh63NL-2UaC6xtxntWC_rU3HCw1t8W6nUQ7cqh1Tpet1a7TKCa6wK8vpQjljdR44NsdXy-PCOCdyHEHKThvYtvHgO5FYARnae0-Ai8PmONrtf5wyKIQPzaNYmHK0M3Mt6v3tcSXBq6yIPE5H7wG2PK_SfZ-weVv4EhCOGjz8=",
            "text": "Excellent. We have successfully identified the general disease ID for breast cancer (`MONDO_0007254`).\n\nNow, I will delegate the next phase of our plan to the **Data Steward Agent**. Its task is to execute Steps 1 and 2 of our workflow:\n1.  Retrieve the top gene targets associated with breast cancer using the ID `MONDO_0007254`.\n2.  From that list, find the drugs that are known to modulate the key genes for ER-positive breast cancer: **ESR1, CDK4, and CDK6**.\n\nHanding off to the Data Steward Agent now."
          },
          {
            "functionCall": {
              "id": "adk-5d22b1d4-173a-4784-98c8-76900a2ea193",
              "args": {
                "agent_name": "data_steward"
              },
              "name": "transfer_to_agent"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 158,
        "promptTokenCount": 2693,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 2693
          }
        ],
        "thoughtsTokenCount": 548,
        "totalTokenCount": 3399
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "c9ff72fe-adc4-4f0c-97f6-b0b37150d808",
      "timestamp": 1761139263.641861
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-5d22b1d4-173a-4784-98c8-76900a2ea193",
              "name": "transfer_to_agent",
              "response": {
                "result": null
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "PI_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "transferToAgent": "data_steward",
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "00111bc0-6113-4e7d-97f5-c5369c191212",
      "timestamp": 1761139273.303317
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CvIQAdHtim_6bdRbwNmfk_vte_FXfO57sug-NguzIyOb5bOmTXR05QNAb_qHvfG4dDwEiR8XPwWgjVczlPz_9t5pHOejbGJNkg-aBGUt47TT69H1_LraAnBJA-2DZlxaUIaopYC-bsT4lz-2lTqsQoUMBsXdbe95hGhG55H1R2FRZkuugwWrxoG3vFjYF1_-R4M_5cZj_geEJVY307DJR0e6XxeDe1qXDVsQ1OtyE3dDVv4Wsa-4H1edwsPpH4mLVraSKfsXGVCduJQTu8Hw9_ywX298riCb58IhfFbLYvon5aTyH-NpYcoVjwgypcjI3PgNtmFf7thNovpX1lEO6ktOdRtyPqeqd3sjSrd9OGiQ0JKhdHurM8mjJ-X8h8Q6jZi8Nup_7ZiwgE-L40iIFXM9lcQFEOCUG5TeRmd3zIv9-R9ftabhhI3gQT6Xv70xArS9MyFnSzHqaCwjLQbRFVvi9RCtwiROHlEAO-GWqiyEoTXHVaqcyxrhH7vhrei36uR06xvFJaAPnfOGjZVJ7WiFtjBqo_eLj0M-8U7ecFGz5VfHVGOu7SgY33xHzmdbYw7erru84_qmVtnpFHVyKdFL1Obuqu8viummuealyDfL6eFRe4uDno13Rs2aWipqR-WSIpMj6-Jjp9r82KDGdxNmStPeBi9_0neS315ocrg2iUVoE_iP3CpgBKUlbuy07zTTp8ejdvyjrlexmknwgVBX7GztK-pv3z9B_XMyVdOxuSpfUW6Ipv7TzIfIKHl-yVi8MKhtksHS-1G2TH3bXXzjA5LmgRF62rB7Oov3-NLaKJTelLlDwhCGbJZGTFz48xDW7ZTMDH_Wudl0If9dXFt8JFfa12Gd9U-XsNH6vz5x1jXkjsRGEBC8KhA6vQnp6MAMBXbAq7pJ0wRp_5Al98XcK49mx1DR9ct19R_EAtys1w19TK8TP6ubhmrCWsnmh7acm6iBn3qkxIxsnl93Ct-YbJb5el3MXAYC5nZDciFlF_H1L_GZD2UxtOoYvvibdoiKBkKiFTwuPM6a32t-aMCiLCj0EGvceYcTgPuw48P0IAdXPa416jXXR7Gp-tZN7zsjbVPBxboCev0wnke7Q6ftjQanzmHqBBoXwJiDeQDN76FJyJhl80tyBklqMJg_9-SVgzAdehE8fRbcBCpH6ssIr_NkOp50cydMznO-i7jRj_JYmWlMTg7vFLYydjZ8z4dPt_DPpboCJA2wBsd4y2KZL10QkN7LbEl80ubcnV0BMbeydWpH3uLTq7AMsBAMmeGQvNJKjy52zBPBcDetRDR7D5m9BXhkU6QPegDqZ-TnuIg1iewUJYLqBYEV-8Ih0bkFB5McTeSc85PXA95hpBKO_HDlwq0ZMY5Lktl4WMfoRyqqvxODVcRyeNu6hGKsNo1upGWyFW8BLyMTmbnrpSRQmHLiYaCfy7TdZevEcj0LjOebPl52I__zwd7odBMGoCKF0msTlRAjOZVLXrqUhbRpxYa_vm4aNtAy8Yml5aZMKR9AVKrX_7svzBaK0XLS-S3lhiVtEpw4B7XMHTJfscTNKr6fFsbqlpIh0alDU0UxSKCCQcvWBBhJYHnhVmEjf3UFP1K2ysTFpAzgeVu7VT2dKWTWfET4WfErTDqfCzFlq7qNmb4wp5V9CSiJib1AOfeojuWkGCdIfzRE2yni6xktoCGqDBfHehcwb0nBZwCPpgSeNBmYgb6pzNXIgfcQANPjF2806bP1EyfRc91ae8VYWVnADvVUQzmN98Zq0dRNZnqrUb9b50sw4tcqdyc0Qn0ZFG9ErBGuhGJATZo-14NwDAWKf6vc33SyZtl0JUe6Wc9WYOtdqE3LdL66B1935fJeP9wLT118OYHj8SihoI0giFZoaclMz7Y3ErZAqzYmekZm3xsGP4mGPPLJMALMWWIZ_PUy2S30-fVX-BWLpEcR9AXY3XYLQ2b_-vzPAZ11bYMAy2Qu3zJM8P249R_qTTFsR_VzamLwMO8DP5X8yliSaDWT3oCjUeFD7s3Y4Loffeh7KBP89hdo6co7stHHExuOcFujxXlQpGzFKBkwfZdx14RkEKGbe7J50JxYIXQcVeMVKSAUsMViPLkUJEKAgqDOcUv4p7gPK_DgIa7AoAFeBTF-uT-zbSDfx3FEITHO_uP6uvYBuP7OPPXVJcfxf_cArqm2IQDSxrZiku1JJhpSwFewWFMvHG0E7xnXifOQPCBxActI27Lr8RBdfN7gietEQKAk1p_IVp8vDxDAdsYmTW2lz6sQemKwKcRn-93LrFeq8M0UR7rfGk1-a9lwdzp5Bn70y376COJb_-cq8vOMRmScqnbm1FI4auBGW7T64lpSfN_XXAT_OppFicT92B1OGY9wcrsSa46wgpjfiGKxjWNlKW9z9nmqYVMnBQ46jg9cAP0SGpgC00IQR1no1zJYjW3x7qsb2o8uIjVsSrsvUtGA9D4pGvRXLlugYCOIenS_WArhVTW4VQcCb-a0zMdhUtGa0YS1qIeVJgcNxN7MHGVyBFXTtwOuytuIO2nN-XkWMXgS1ERzcQhOGE05rFCSWhZx2jAJ7MVkp7UvSUm5xQk2PrUOiOvPdnHZ1zAcSFxnDC_pkdaqGCz0OaKinwMlzPc46m7Gf8jLMpjsPv-UWuWzJsxWO3niG_lxeBKarbW74fuiCnc1b6Y7wBMzdLMVXxoo5f9tyzbMCUFVP1Clp5oC92hEPH28ikZ_IhJM792TKUzEHwu4zukrIJvPDpPeIYdz_0mdxk_vLSBZW7PzEgJOjC3Df44cJCE6oWY1LxYxQx6ehGQEZDYFMPEo6owpsd4wWDoif6vw-d12VS1yzoK08iv5IThoFp7JchSYQZ5746KKdRkwSKd5VwsSIBzBjRY=",
            "text": "Okay, I will execute the next steps based on the Principal Investigator's plan.\n\nMy task is to:\n1.  Retrieve the top gene targets associated with breast cancer (MONDO_0007254).\n2.  Identify the drugs that modulate the key targets for ER-positive breast cancer: ESR1, CDK4, and CDK6.\n\nFirst, I will retrieve the top 15 gene targets for breast cancer to confirm that our genes of interest are on the list and to get their Ensembl IDs for the next step."
          },
          {
            "functionCall": {
              "id": "adk-24bd010f-bd41-4eb4-9195-5389d983c1c8",
              "args": {
                "disease_id": "MONDO_0007254",
                "return_ensembl_ids": true,
                "limit": 15
              },
              "name": "get_disease_targets"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 159,
        "promptTokenCount": 3738,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 3738
          }
        ],
        "thoughtsTokenCount": 602,
        "totalTokenCount": 4499
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "20676524-a71b-407c-b511-23510dabeca3",
      "timestamp": 1761139273.306635
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-24bd010f-bd41-4eb4-9195-5389d983c1c8",
              "name": "get_disease_targets",
              "response": {
                "result": [
                  "ENSG00000139618",
                  "ENSG00000012048",
                  "ENSG00000121879",
                  "ENSG00000083093",
                  "ENSG00000141510",
                  "ENSG00000183765",
                  "ENSG00000091831",
                  "ENSG00000141736",
                  "ENSG00000136492",
                  "ENSG00000108384",
                  "ENSG00000039068",
                  "ENSG00000142208",
                  "ENSG00000149311",
                  "ENSG00000185379",
                  "ENSG00000171862"
                ]
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "f0561c5f-8e34-407b-b61e-f7ef72975646",
      "timestamp": 1761139283.963738
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CrQFAdHtim9HTqvqwscv2gArbnHHSMEYrpxpLUF4nzp-1of8Sn2OqpFpWtZ2VkhXABKgJG6McRdFQV4w3ZLQb_IZ_tfIqv4VevRLobtWmYU7OBi-11XUjeRr9lX8KxyqEz_KJ3RCQHSjqtKUxyO0XlWFBEtKkgJQ83wOS7hSmU6nobs4F7YrO3sAzWa0Oy5CHm9ZFG4sIu-ZrGucCD8AeO0MAALmB4cJ9JMS-_EdoOJwb5_ma7ywFBINXXcveVv7d_mX1kjoIgq3dLn9fiW2gNsuD-nRjGb3BnMRVmqxro6lO3Jl0hM7QLWjN_XzpSZuMW004EA1T_5tEja-WNRC9LR2HZcDtVXMMNQtGXelKAC_kKUL2SA8Lym8-0So_ygY21O8U_jIa5Lg-AkdpbcApXdDYSYXYdMWaO-L9llC1kR6fzfDD0Zv2jgUDoU7TQCC2XIWf-gOn6ZXIsPip3bB9r5jn10i5ykENHFGXgrW4c4p-JI7nu6D042_u_UziuUmqj6nsofn9fhhQVydwjBmJaH3065hOPkyivREpS8mVRzh1awbOffHMmiV_K7rSABWbzj3TL2FoWKfuFsicegKY1KZg5kIXPATQ-_q9VnWd9xr7eugLByhQ_W4UOOPFtpBA_Dw0o2MJbL7zAg_-p5CKBzdz7Yh3GFSyGDsZgcUgiKac_f5w0vTHGwAzYCRBDaDjDif1Ou8kHatO-rNkejJYkbW3YY7-AWyfrVNNbyTHCOMS2MDI5lON0s03sTohN9ThbeCuG9SZy3WUGWJaHaTPU67ByxYhEvFkf8hFAdutKz-jEMIHgpTwodHILxaDo2TXbLdsVyh16D9_f8th9LMumTC9BEh4JRCMEqKePbEPx87RpsQ3NZXQKPTxvWLG1i8dgXg7-etKRjjxHXaE1K8ODyy7x7J3rg=",
            "text": "Excellent. I have the Ensembl IDs for the top 15 targets associated with breast cancer. Now, to identify which of these IDs correspond to our genes of interest (ESR1, CDK4, CDK6), I will retrieve the same list of top 15 targets, but this time requesting their gene symbols. This will allow me to map the symbols to the IDs."
          },
          {
            "functionCall": {
              "id": "adk-c192514d-18e4-46a8-9227-bee2280f197e",
              "args": {
                "disease_id": "MONDO_0007254",
                "return_ensembl_ids": false,
                "limit": 15
              },
              "name": "get_disease_targets"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 121,
        "promptTokenCount": 4137,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 4137
          }
        ],
        "thoughtsTokenCount": 196,
        "totalTokenCount": 4454
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "b0f4152b-b8d5-4bc7-ba31-ba7e536d942c",
      "timestamp": 1761139283.967001
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-c192514d-18e4-46a8-9227-bee2280f197e",
              "name": "get_disease_targets",
              "response": {
                "result": [
                  "BRCA2",
                  "BRCA1",
                  "PIK3CA",
                  "PALB2",
                  "TP53",
                  "CHEK2",
                  "ESR1",
                  "ERBB2",
                  "BRIP1",
                  "RAD51C",
                  "CDH1",
                  "AKT1",
                  "ATM",
                  "RAD51D",
                  "PTEN"
                ]
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "35c917fe-325d-4c9c-9543-4a09058c70df",
      "timestamp": 1761139288.48409
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "Ct8SAdHtim_8FsuUEShHpx1jM55uaXgQkokP29Adl7aTUBOYZ8cOA_xlojrDk41oEvgjVYyGrMAbVw88MPhGnpe8_gdaHA8Et5iJu4ndJ5UPg0KvyVW0J4d7YB2wxrx5LtUdU_dqDfIyhUvqU550aeNs0hh5iBe3sxAuOjJkE7TheSyuhtgviygXrLZgm2U_2oiCii4_vJZy6hg3HXtkuSkAP7hO-_jM0e7LJhROdjU_iGaMzbSPp966_eEAW7Dmfq2R8LAvi-35j5MUTfsh7wrnYZYtrGrFWE1G4Py0tORkRTltZw0PRSIqZT1pAScTjLGHCk_E7VyHT7GNl0dG7eVRvCjnkhRMDQiMDesAGMymFwP7Nxte_2PmDVoRxZnt8vnkkv1IvoL94GihrDWcVUekys3x3PyLjsz0KPk7EAh1yTgGJP43tmeYzNWVDYXOevK3I4ajKo0tTs-EQfVNr0ejvPvarub6ZEhGM3IWcGxlvxNaOZa7V3Ovx3ZXA8fFt-rLmubrQD0G5kZ2PXySpN0CuXT06Cxntf8zabezUpPIM1i1EbSMTdESwwavtd0ZcX_dZbabn6TQiOdC5wC9fZ9K2xHnRZ9Y9xtF2HVwjvg2GZGjinIHfs5HSrausotUkemsLfk8uzotIOiC5VHckjodj8RUa9HwWLWLQSQksWPAvQGLPU5fkfsajF_mNHqsfIl83BeMdkjok9WFbZ3tXyBkhVlQZaDK7SxRjClvNeZW328L1TItxak7p1yZd-rGQOtjz4u_pJHAIsDoCkuWPobeVF5XpzUWhU1ZYjvd2p--GfW8k_1YCJU2KYenu9mFXLSwj6wOI_7i_T01lksxx_aoz215RToMg_lV01kE2Hi437XpwObeqSIrYfeOSV0_S5eQUzRJDlY4dBhaeTizKdigPorfItKVik1rGfvJraz1HO4bVG3o7CRdLDnXuDh79gNv5UUxTbv6f47mOqaW6Dw6ckw_Pqi8moGzDKf0tP5NG0eiASQmohzrV24mOG38gsb3kfZYonOlyNvD3dpNCAHQKV0cCAVFPr6lU6K_G9IRc0Vaik5SydSTxB7ckgwrletZT-UQhkLt4eSdEpZLS0WacEep3dk2GiYaEMr-Q9O2cPbSWVu7BUSI0lKk3dqtqCIC-SPI3pZbnVamUPsA253HfgtpGteCVxjcNX09J7kk5Aa8liUKxkzSu7zwtHwgQaTnCJL5AJ_kgXl9dtSr7jdkZDSr4wUw9h8V5tLMsLHZbDsxQiNPehXuTfN9kZhyvoLH0Rvsy29pWedLP_HN3Y3YMlFpYnH2-OfJtyocndCegwwtapxB76S18GXQkDnfI1OSLHsQ5g-7GR8ls_McZZe2HKLax1WRnnByjVHM_xD2AxR_4-zEil2s3htGLh_7jmYD8S23uP1uYDLWTJWnXbH75pSP3ndj1cjmPTZvkwC_-lRkKkuh3-cLZ1sRe5HjD8XRBNUWVAPr9-dhYVz_OClb4ciHFbj46Gd2W6aq9L5q5T7UjDZBM8psLJMTv1jrr3NsiCDHDEDSWRRXYbb38QJ6G1n-QhKpY0TZftMymv0wCZ4eSmkJyNK4-2H1WStVZ3QtuSHUfjThBSJAdPru7ttioJeMpJki_maAmZBqI_TGlU92TJMaC6ZZBLl-YnUNrev3kEwdB8pfaonmLMzCksYkRAJxCb_x394GDfZqkpvA03PyQkI8j3oPMDBASpgFOJIcuRpeCdUaMgxTxXstqy16Vr9kWxICCDlRvJVi79tm2y9O8YjoVrudHOiRYYrm8bQ4-8jTjKpTdayuoR7cUx5hqjZRLvQ2Sf11GSZs-hy0HeNMcJqIUC5nOYISnprzybRfCWooJrCh0Jlq64HyQPWFbv6RGykgYewXTCIxulsOej7lqPWwPakdCz04Q7STvecAFCIuw0Y-wNnXg2lnB34KXCswtTFAR3NJ2z4e9jrPP1TO7Sp5Z9YQSabjvD2Qnb6spzZLD37fkj_0iTuS2CtGG2Dp75Vd-nzbPsq1kAvHY8gDrKbdUhkf19cT7OP5WC8IcICiI1KMk_0DXgOeqx3jbbxRkRjT1gg38ofcVRMC6xHDJNjKu1JSVpejCLj30RJRCu-63dgbV5JvZ7Pvnw1_Vg9E5IRT3mxU9OtAMYnupzKt-cHNLsIDg-DdOYNBSivz8ZDfDmi-KuVkK-88bPcV-9t6rC_gf4PiwzqFf-igB8Ijsen42MSa7AYtcQEH64VZcdl7fZx5QSfPxf0_vaLZm_LufpxVhT6fNfC6c5LkbZ-jMEfilmiWpI4cjm-FuLCbT4VkGxgXEXvVLqx-rwXR0nsOMk01nZ3Z_OlBionW9CKjss9z0Q2BaTwTiCZPOFomTm6hGAyrPmSucA7o7Ss_CSOlB4i5h8ttlya31vYod0KAGwezUlDxmKFUoYMwHY_ymdRNfcZtwU7qsOfpL5lc6FJhYla1BAEBEre-FVPVxo94OJqOPVY0eT_t-SIev6D3G0AXqnzWFXCMpPr7RTt_ntCaSQP3xz7pTVnSTV4OMi-JMxwkyo6hz8n68zwAPm8CXFoyf56m4h0VhxmnT5es3d3PPA7QRL38fJYJ_VQiGtM7YwUJpl6lItiAxlAjUj1DOXyrvpOi22bPDmhFimckAR_HkJxTLMpU8SXJJidYm4Je3pQroieTHcT-FdcBJlKsoKKQsrwER5cmSBJ2d6cBdHez9rSnKL7XBlrFQqQKVYkd3uKeNqjSYULV7urebuRSyXan76pG3cHF3U8v5I47t2ADoe9wXQ1YLOcLC0xtMZq_L6R-UGzgHw2QIQUgh8tn2uCRcC16sVQxb_dIJM59dfgcLealQk5jVjMQMtV1EX93Pmo4gY8dAqPyzICjRqgl_mqDOG42NeHU8bZKZrNip5d-IeKs8_xeB7QEBnRBBAuRE4gq2HwBbZyNUMBHqpMpHdbC9mI06U0A7_-bHrTs0yAwhXMSa8MjfdqOasFS8gh8CQtLUCDSWQ3ykxXlTn6UIqXUzTW9WNp1ZiCx0e2fPijJzHdArThJm8hjfB7CSc3l1oM8TzDVrTjAwhkJzKdOor-9MrWPgfD1ulgpwdlG7hN80re3j7yZqZPCn8R3ak4zCG2zi8RangdRs9yVr9fBSTRf74zq6owGCBarFBw9Rp59lUYU1DZvKNCRv-yoabDdfPu0K5OK1EKNGxKSTHI=",
            "text": "I have successfully mapped the gene symbols to their Ensembl IDs.\n\nBased on the results, the Ensembl ID for our first key target, **ESR1**, is **ENSG00000091831**.\n\nThe other specified targets, CDK4 and CDK6, were not present in the top 15 genes most strongly associated with the general \"breast cancer\" disease ID. I will proceed with the primary target, ESR1, which is highly associated with ER-positive breast cancer.\n\nNow, I will retrieve the known drugs that target ESR1."
          },
          {
            "functionCall": {
              "id": "adk-fc651644-e5a8-47cc-95d6-e0d59533ba3c",
              "args": {
                "target_ids": [
                  "ENSG00000091831"
                ]
              },
              "name": "get_target_drugs"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "cacheTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 3376
          }
        ],
        "cachedContentTokenCount": 3376,
        "candidatesTokenCount": 152,
        "promptTokenCount": 4347,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 4347
          }
        ],
        "thoughtsTokenCount": 858,
        "totalTokenCount": 5357
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "c3c18445-08bb-4ce1-8fbf-629e5c32729f",
      "timestamp": 1761139288.487402
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-fc651644-e5a8-47cc-95d6-e0d59533ba3c",
              "name": "get_target_drugs",
              "response": {
                "ENSG00000091831": [
                  "FULVESTRANT",
                  "TOREMIFENE CITRATE",
                  "ETHINYL ESTRADIOL",
                  "CLOMIPHENE CITRATE",
                  "DIETHYLSTILBESTROL DIPHOSPHATE",
                  "DIETHYLSTILBESTROL",
                  "TAMOXIFEN"
                ]
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "51ed9a1a-4a85-488e-ab0f-0dc1b4875d5e",
      "timestamp": 1761139304.116606
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "Cr8PAdHtim_50pq7kGVTvvPC0wpF1LYQ5Jz-HhP-ju9LgC4GAGPggWh4156v1tXXqupNxA3qzgGkuqIhNNqM_78PRGuQBUPuA6nibhpRNXvTySVS9ZTiN_uQ98ajpFaCViFtXCbe5v-2KDEhZhXOoOt8XA2ofdWft1l-6zRR1GIzi6xtGRD3dqRMFM2RwdZ0dwCcO324t4WaBGQPDvsj8nFx3BLc45_feoY3kOI8rBmQzg35q9FWScWYYHH3ovmrxbUPPPXwhX47IwKBBwRWp0m6UUu2WrZKmQDNSuqv-jmrAp5mfOoH0SiYH_-GRuPvKtO-daYLIfoyrYl8DImxi-n5Io937i8-tWRrnz6dp6tF-5DnvzwJVL_iTDXKAPmzppvLtejavZX4oiiuTvX7PYcUZQuxauzcd1w9hHSobmck6TOPHBHQ4WJuYwHbzbFtPupmLemUjBBLa51ctA3dyq38bdmLj-KAg6drxDfFThg-bdUsvj_kH51X_3eoG2GYn_Dqgt_bVO6JKnxrfuhuaRDo5ldLAXOlpaSmwMQDQZTTzc1v1pXDA5WmxRkGKCEh5LOiajSG9Kdv_7GNJoh6R2svoPWjzWNyDgJial5Km7Cx1eI_cgP2mjdt96dATkNp1Gu6GYJ_OuLMSAzvtyYqVvF9sr1pi7Bw6WSAOMJYHhqcDVJXUnB0Gccsgi7H49k0Bprtz0IOmrUVGYEfrvM2jn-6PhdBlnWoaf0eMU9SM_Lc77aUQUgDwWDQ03xvFQZDFbRHHfcVIRto_iIenRWZPz5B8iUUCGbo4ITdfDcZNW0BEWhmAcDnNw1eQdox_Cuw_I-lSwIyZodtEkciM2PHVf2rWtTqkJPpH8EgXmA5Jtiv_Q_znbsHq6ElEiaxVebDekEEV81LtCUoROWAUnOYJbcNVGNI5EOfpMmKQIZ1-hWGnuvAJjnBUaWvqFu_epW5qFOzkv0kld8c9G0W8UztJrsyKVJVa9yRA6I0seklq4m4Ay4qRI5AVb4Xgpa9zOPpaVOwvzEe9V_ejGzfGB3ZH9XZmkkxE4yjijKOyYlsMzMtHuOepBVtS3aZPvtlf6w1SHXbfwVnqSa-cvp27OMSNw4LhzjcWcgbakwrohdVf8PDwZRskC87akctTyTabzOAOv2mLRytFl5k7-Ne5A6-wcRHoFuHPiVGJXPo-94lPjDIBLWKMC1bJEd8zQ5H9ys8ilEqCU9NExEo7q2nC0_AQS88HHSI-ucNcnFT7G32WFXVfqJmnntJucAZ8_BX__0d7mG3ZuXI6qy5JDZy3ATmV8ilScwMgA-027uMIkGrwucpqA2-fRzafrKb3bRZpADQr7VvCKaMgcDxAkO9lBH1JjJmr6mkMZUPQ0405jgjDtT_oylF0Bx7nbsC2VOrutI55lXkbZxaaH-0ckBLxBM9Us3iX3uNZJpAifSHnznFsZKBIBKeEQQ40Z6AGKUSVb9AmTRNiPzXJPumHcIJYEYHz69-pSXSYxblvNbR-VEEvZNl2fxVO6cGkElMpyYjb3DbVd4izow7Qkjebl0S_QIEs_c3FIZPU1GOVxN93w67xugkXj07w2L9SN4FDlB3xSnn-COffU8zHPRhp7tEN-ZBcdCgjsmf_bMPvr6UsNZHktVXU_ZpTc9WdJxGKQx0wg3AT9Qg1OaaITigMPS-5u6PnrPRKhwGXRa98jg6v_89wK8R3n8r2cZRJELBMzmNJ6t35K2JdGi8TMfN7R9UAqCILXh-MjesJkQ9hv_N-edL3kWgOZmzhtPpLwywRaBv9iVRJ2miXFByiZSdI2A9zc1-RGnV2izeeucfAZmzc2n5FQaILEHfQi2BJR2yy1cJtIvwHzkp2qtCvk3d2jAiV4ljJzvnu_CwDwPEja2bugusvb8WC7o9vuMscvSQksoYDnJtX9mHCAuUtCD53wCC30E8lvSB-CnYrYAzBjRBSV9_UWFrunZ6-jAK6ziyQbdd3l0iZ_z1AiqSRVu99NzsGIZ3K7YFSKATfvi42Hc1cvoIYSpoG003lhtn4sd7OfVhRWRW3nWN8uE7iMFVorv_L5zoehJzHOwvBIMm2Vjb7tUvcDE-TUAXENhb1II1zW2WnYPCrY3zYTIqqOqCosHXgOGvNn-CLi0AsVTFZaVQUWf7uxhXqpAfqZM7iv3TjsLC9erfiPOZK5iXBty8IMOUV7duFPjaHPgQfbA296RKLXO7DfEHQ5-gMcBMUjwHfydhEuPVb1WnVkq4Ng1es--9_WqZUhwat7Y8YvQsVhj2I5x88gGd7zj3dj0qHUB_YVTnQ71tbowQkiOtyCYdOobdIPsD8b1tjvCyQbW0i0ks3DgChdwCb0Q69P7ZCD9j1KATVH_FkR_YbObcRsK1Uoxl1BYo5w0irwZvguRK2IdiettmMGAJNYrbsxhfNPR0G2RK2Z4L1j63NFxVouoiwEcy4S6dYvkwkttX-WyTGfYDF5VSabI6pTa9VJVJz34V5--xyuJXWPUd22L_MnZe3ywaFEaHNwoZ8IVIcQPe1ENnmGE6c-ugnrk2cQSNg6cyuEIYIcBGmnZPmwheT8h6vv0Iv1EhuiYw7T84d7slujTcMxf5xv8zfpvnxq4g_qDch6o9sRRDS26CTHtBT2_cZOY_u9pMlXUX",
            "text": "I have successfully retrieved the drugs associated with the ESR1 target.\n\nHere is a summary of my findings:\n*   **Disease:** Breast Cancer (MONDO_0007254)\n*   **Key Target Identified:** The gene ESR1 was found to be the 7th most highly associated target with breast cancer, with the Ensembl ID **ENSG00000091831**.\n*   **Other Targets:** The genes CDK4 and CDK6 were not ranked among the top 15 associated targets for this general breast cancer ID.\n*   **Drugs for ESR1:** The following drugs are known to modulate the ESR1 target: FULVESTRANT, TOREMIFENE CITRATE, ETHINYL ESTRADIOL, CLOMIPHENE CITRATE, DIETHYLSTILBESTROL DIPHOSPHATE, DIETHYLSTILBESTROL, and TAMOXIFEN.\n\nMy task of identifying the key targets and their associated drugs is now complete. As per the workflow defined by the Principal Investigator, the next step is to assess the safety profile of the identified target.\n\nI will now hand over to the **Safety Agent** to perform the safety analysis on the ESR1 gene target (ENSG00000091831)."
          },
          {
            "functionCall": {
              "id": "adk-bccd3fca-edf2-44ce-aef4-dc1fccd5dbc2",
              "args": {
                "agent_name": "safety_agent"
              },
              "name": "transfer_to_agent"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "cacheTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 2946
          }
        ],
        "cachedContentTokenCount": 2946,
        "candidatesTokenCount": 297,
        "promptTokenCount": 4586,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 4586
          }
        ],
        "thoughtsTokenCount": 587,
        "totalTokenCount": 5470
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "8ef9ea7d-66e8-4a17-aef3-948697e430b0",
      "timestamp": 1761139304.119611
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-bccd3fca-edf2-44ce-aef4-dc1fccd5dbc2",
              "name": "transfer_to_agent",
              "response": {
                "result": null
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "data_steward",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "transferToAgent": "safety_agent",
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "8661228e-eaac-4479-a7db-5e5339112b12",
      "timestamp": 1761139318.13922
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CoUNAdHtim-oSLh1VI5uJ3IeSAaShi-GRU3nZZJhNsfuFs_7w1xootrQUHqjV8Tkpm4-teZJeG7o_yAQC-OBnMHtgNtJM-bbxjWbQ2OaMiTC1wHZAbIBFXNnYfR9Xiwo0YuixIEV8Pijfjs0wcA7jmWRBjkYeoSS1eAeuE1uBAtuIQRcQEoQxyJmFaQ-Js1YilGe0mviCgIOLvNnDKeT18Z9U92N-97xiXgKgAsOsG42sZWvE-YdB5UHFXT-qHhdglXXw0z_2UJWVcZ5bI9FNciRr7BY5w_43EuVoKSzpgjhnHc8eES4M2zOBd7cwyLSbepLL9tD337lx4ogMCJ6u-YyfWliZOtCmHf8NskR57B3dIxozFzq2s_5K_dh7-V2zBoKZqz8802ekoOHxO9HA736qte1rzvJYTXaBpsQVA5KqUg6LF8LIhyCYK9gI2qsYef6tOPp4FHR_DxqWSM4rkXlmSTf1N7nGiMttz7l88aeh5MHuNVNiW1G_5xLt0-W_gw_QlZpkQdtOqI-vi34YLWD7DIJCs2Y1sGbkmXEQfjYVj8BXeGeWUl9PD7shEh3or6eNiqca7Dnrlu8SXsBushhjuP2A_VVJ_G1HliKY6yjRVQO5KDhUWr8nbdpH1pWm1iK7NVcQgzJQrppMCG5dHwvc5eFoV8t8nYcsDtFlBdIxf17eLxP2fWoAhxPK_-imReZHzBtMCx0XTopaJIf9E5XHy9-JDFIpBe40ispnprg3pjLplX4gA_7LPFhO17-dm-z5tJMeKLUjkYMpBslthTNZGe22gXvl4jDlIamar4whW06__FcTkmQ1kU_9h9mfK1IfuQ66PejDQBHTOOo478odSpznn18D3MyduqlO0mva88KA2xFMYRTeJwrKtkFNJ3JH2Y7U8ZfIk2OH9cxWpANw5DWOT55Y_UCF1g9BZLV7L9w9WSzaCCO9Innr4b8Hmr0i83OvLPYf9xMHrxU2G1VLExhGINdMfr3kpPRXAB1pcIlRn-puJ2eHK4L-vbVCEUxuxsL7uZesRpWZbVoaXkv3qBcuytiYRfoYaeCdB2cDfsZO0zLDhLAlVY7Qj4X-yI18uqh_NhVYam9MNjBaXigl6gIenwDHBpQNc1v7nriPIY9RzSR06NOGc4dSV_tGBobxrd-AsjFY5WOJIOmQqM8bMHleCSkucf1nvvHvFjXFNsJLTGei7h6oUc9RKbYe_W_Ej-2KITchowxkF8XnS9AA1Ld7ILRM7F7K6QkXMHdiK_lwA0e0mPTIzpBVTsPJ8t2U3vxkFKGaSujmaxwE237PBoeL3MF2SLpGsyvy_Yvw45FSeSi7n28PPPhjZ5lo1fBD9lQs0e8gOuYR0VKMxrDnvnhhAWz8rdwsSALoiikXSso8UW21APTp-9DTKhuaLzViITb2aEndXkxZpaIcLbpC3UZHosoAhR0amYKLsrqS0eEXKDli26EFyIfdEbQk7vD3izGpF7VwPIUis5WFLdJRiDoEY4uIbmMTIG5Wd9aSi-_34dQQMWahemxijc96Z8JBla32AjbF7vR5-hzEQsHESeMP_7yqU0eQxEsssXqCX0jLi6-kdogRg5ykrC1kdyLidK7KJK2Uk4b5DPvC9v8LQkmRtQnpeBmk01bzwEJkMhPDficEWICziVgtbzxFSUx3vLLWyA0aAYWhC_T9ybKL0yL0MthEAFszk0FHtcAnsOlsTefUni6CZrkM90CS2quveLbI0qE0NxrkjFrVpZUqOItCjU5Jm7sAJw8ehUuyJGvPEHYd6dZ0KbTjTuAXp4WCA8hZLIWqECGxgGl5xqQTvq_na9JDKnEEOmz83PQbcfkdXEbr8hIVmkkDgKc2RWCyGeqwsnBHWvxtWmAsO7E69rfRIibxEyx_FG5cCHcw6rlQ6ZW48Eb-OfmNWyVWiPh73PTh9hlJSRz9dRhveVjFtY9INKZ5fHVnUmXiDNQHKJIOmfi3D8x4-QNZBUcv_LHQLneVHpFfFG7StMS276Sa4yaZ_yAOC-QaduqWCSpB8degwWLDkuyHtBlfrw_C1f_7m4Ie8nF6YYacN06jRRe8k_nuZQFvRMj4k_3vVwTFsnoQTZ4LuwA7ewFjQ3aFeK3f9W2IB5G5WRw0RuRWTsXULxFmuFHqfhqqi4RWgss5PAHIlY1NEc3dl_COSM0Cz7732uYh7NSvcUMuxZa0WyWaMp4af73SojhoPNhx2gpYnZZfl-AAA==",
            "text": "I will now proceed with the safety assessment for the ESR1 gene target (Ensembl ID: ENSG00000091831), as requested by the workflow.\n\nMy goal is to retrieve and summarize the safety profile for this target, including known toxicities and potential risks associated with its modulation. I will start by querying for known safety liabilities."
          },
          {
            "functionCall": {
              "id": "adk-86ea9e2a-8afe-41ee-9de2-dfd06851888a",
              "args": {
                "ensembl_ids": [
                  "ENSG00000091831"
                ]
              },
              "name": "get_target_safety_information"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 110,
        "promptTokenCount": 5095,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 5095
          }
        ],
        "thoughtsTokenCount": 397,
        "totalTokenCount": 5602
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "safety_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "92eda40d-84ba-4778-9944-7a38cebd947f",
      "timestamp": 1761139318.141204
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-86ea9e2a-8afe-41ee-9de2-dfd06851888a",
              "name": "get_target_safety_information",
              "response": {
                "ENSG00000091831": {
                  "id": "ENSG00000091831",
                  "safetyLiabilities": [
                    {
                      "event": "regulation of gene expression",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "OT_ERa_EREGFP_0120",
                          "type": "cell-based",
                          "description": "OT_ERa_GFPERaERE_0120, is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0120 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology."
                        },
                        {
                          "name": "OT_ERa_EREGFP_0480",
                          "type": "cell-based",
                          "description": "OT_ERa_GFPERaERE_0480, is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0480 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology."
                        }
                      ],
                      "datasource": "ToxCast",
                      "literature": null,
                      "url": "https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data"
                    },
                    {
                      "event": "decrease in high density lipoprotein",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "tamoxifen induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842246_A_G,G"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "Increased, adenosquamous carcinomas of endometrium",
                      "eventId": "EFO_1001512",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/167"
                    },
                    {
                      "event": "Altered, Larval development",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/29"
                    },
                    {
                      "event": "Promotion, ovarian adenomas",
                      "eventId": "EFO_0002507",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/165"
                    },
                    {
                      "event": "Promotion, ovarian granular cell tumors",
                      "eventId": "MONDO_0008170",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/165"
                    },
                    {
                      "event": "methamphetamine-induced psychosis",
                      "eventId": "EFO_0005242",
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "methamphetamine induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842200_T_C,T, 6_151842200_T_C,C, 6_151842200_T_T,T"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "N/A, Breast Cancer",
                      "eventId": "MONDO_0007254",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/200"
                    },
                    {
                      "event": "azoospermia",
                      "eventId": "EFO_0000279",
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "Alkylating Agents induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_152061247_G_A,A, 6_152061247_G_G,G, 6_152061247_G_A,G"
                        },
                        {
                          "name": "cisplatin induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_152061247_G_A,A, 6_152061247_G_G,G, 6_152061247_G_A,G"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "cell proliferation",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "ACEA_ER_80hr",
                          "type": "cell-based",
                          "description": "ACEA_ER_80hr, is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology."
                        }
                      ],
                      "datasource": "ToxCast",
                      "literature": null,
                      "url": "https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data"
                    },
                    {
                      "event": "Decrease, Population growth rate",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/30"
                    },
                    {
                      "event": "Increased risk of thrombosis",
                      "eventId": "MONDO_0000831",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "less bone mineral loss",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "letrozole induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151916333_T_C,T, 6_151916333_T_C,C"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "Decrease, Population growth rate",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/29"
                    },
                    {
                      "event": "impacts sexual development",
                      "eventId": "EFO_0000512",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "regulation of steroid biosynthetic process",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "CEETOX_H295R_ESTRONE_up",
                          "type": "cell-based",
                          "description": "CEETOX_H295R_ESTRONE, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology."
                        },
                        {
                          "name": "CEETOX_H295R_ESTRADIOL_dn",
                          "type": "cell-based",
                          "description": "CEETOX_H295R_ESTRADIOL, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology."
                        },
                        {
                          "name": "CEETOX_H295R_TESTO_up",
                          "type": "cell-based",
                          "description": "CEETOX_H295R_TESTO, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology."
                        },
                        {
                          "name": "CEETOX_H295R_ESTRADIOL_up",
                          "type": "cell-based",
                          "description": "CEETOX_H295R_ESTRADIOL, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology."
                        },
                        {
                          "name": "CEETOX_H295R_TESTO_dn",
                          "type": "cell-based",
                          "description": "CEETOX_H295R_TESTO, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology."
                        },
                        {
                          "name": "CEETOX_H295R_ESTRONE_dn",
                          "type": "cell-based",
                          "description": "CEETOX_H295R_ESTRONE, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology."
                        }
                      ],
                      "datasource": "ToxCast",
                      "literature": null,
                      "url": "https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data"
                    },
                    {
                      "event": "larger tamoxifen-induced decrease in total cholesterol",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "tamoxifen induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842246_A_G,G"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "bone mineral loss",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "letrozole induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151916333_T_T,T"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "protein stabilization",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "OT_ER_ERaERb_1440",
                          "type": "cell-based",
                          "description": "OT_ER_ERaERb_1440, is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology."
                        },
                        {
                          "name": "OT_ER_ERaERa_0480",
                          "type": "cell-based",
                          "description": "OT_ER_ERaERa_0480, is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology."
                        },
                        {
                          "name": "OT_ER_ERaERb_0480",
                          "type": "cell-based",
                          "description": "OT_ER_ERaERb_0480, is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology."
                        },
                        {
                          "name": "OT_ER_ERaERa_1440",
                          "type": "cell-based",
                          "description": "OT_ER_ERaERa_1440, is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology."
                        }
                      ],
                      "datasource": "ToxCast",
                      "literature": null,
                      "url": "https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data"
                    },
                    {
                      "event": "Decreased sperm quantity / quality in the adult, Decreased fertility",
                      "eventId": "EFO_0004248",
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/67"
                    },
                    {
                      "event": "irregular menstruation in females",
                      "eventId": "EFO_0010270",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "tamoxifen-induced decrease in total cholesterol",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "tamoxifen induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842246_A_A,A"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "skewed, sex ratio",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/52"
                    },
                    {
                      "event": "Increase, Endometrial adenocarcinomas",
                      "eventId": "EFO_0005232",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/112"
                    },
                    {
                      "event": "Altered, Reproductive behaviour",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/29"
                    },
                    {
                      "event": "bone density loss",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "exemestane induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_152103343_A_A,A, 6_152103343_A_A,G, 6_152103343_A_G,G"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "regulation of transcription factor activity",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "TOX21_ERa_BLA_Antagonist_ratio",
                          "type": "cell-based",
                          "description": "TOX21_ERa_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity."
                        },
                        {
                          "name": "ATG_ERa_TRANS_dn",
                          "type": "cell-based",
                          "description": "ATG_ERa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology."
                        },
                        {
                          "name": "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2",
                          "type": "cell-based",
                          "description": "TOX21_ERa_LUC_VM7_Antagonist_Specificity, is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_Specificity assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology."
                        },
                        {
                          "name": "ATG_ERE_CIS_dn",
                          "type": "cell-based",
                          "description": "ATG_ERE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology."
                        },
                        {
                          "name": "TOX21_ERa_BLA_Agonist_ratio",
                          "type": "cell-based",
                          "description": "TOX21_ERa_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity."
                        },
                        {
                          "name": "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2",
                          "type": "cell-based",
                          "description": "TOX21_ERa_LUC_VM7_Antagonist is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology."
                        },
                        {
                          "name": "ATG_ERa_TRANS_up",
                          "type": "cell-based",
                          "description": "ATG_ERa_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology."
                        },
                        {
                          "name": "TOX21_ERa_LUC_VM7_Agonist",
                          "type": "cell-based",
                          "description": "TOX21_ERa_LUC_VM7_Agonist, is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology."
                        },
                        {
                          "name": "ATG_ERE_CIS_up",
                          "type": "cell-based",
                          "description": "ATG_ERE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology."
                        }
                      ],
                      "datasource": "ToxCast",
                      "literature": null,
                      "url": "https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data"
                    },
                    {
                      "event": "breast atrophy",
                      "eventId": "EFO_0009483",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "breast tissue growth in males",
                      "eventId": "HP_0000771",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "Hot flashes",
                      "eventId": "HP_0031217",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "azoospermia",
                      "eventId": "HP_0000027",
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "Alkylating Agents induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_152061247_G_A,A, 6_152061247_G_G,G, 6_152061247_G_A,G"
                        },
                        {
                          "name": "cisplatin induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_152061247_G_A,A, 6_152061247_G_G,G, 6_152061247_G_A,G"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "osteoporosis",
                      "eventId": "EFO_0003882",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "receptor binding",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "NVS_NR_hER",
                          "type": "biochemical",
                          "description": "NVS_NR_hER, is one of one assay component(s) measured or calculated from the NVS_NR_hER assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Lysate-based radiodetection technology."
                        }
                      ],
                      "datasource": "ToxCast",
                      "literature": null,
                      "url": "https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data"
                    },
                    {
                      "event": "tamoxifen-induced increase in triglycerides",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "tamoxifen induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842246_A_G,G"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "regulation of steroid hormone biosynthetic process",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "CEETOX_H295R_ESTRADIOL_noMTC_dn",
                          "type": "cell-based",
                          "description": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC)."
                        },
                        {
                          "name": "CEETOX_H295R_TESTO_noMTC_dn",
                          "type": "cell-based",
                          "description": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC)."
                        },
                        {
                          "name": "CEETOX_H295R_ESTRONE_noMTC_dn",
                          "type": "cell-based",
                          "description": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC)."
                        },
                        {
                          "name": "CEETOX_H295R_ESTRONE_noMTC_up",
                          "type": "cell-based",
                          "description": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC)."
                        },
                        {
                          "name": "CEETOX_H295R_ESTRADIOL_noMTC_up",
                          "type": "cell-based",
                          "description": "one of 12 assay component(s) measured or calculated from the CEETOX_H295R assay (11 hormones and 1 viability assay). It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The concentrations for these components have not been pre-filtered for the maximum tolerated concentration (MTC) based on the MTT assay (_noMTC)."
                        }
                      ],
                      "datasource": "ToxCast",
                      "literature": null,
                      "url": "https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data"
                    },
                    {
                      "event": "bone mineral density loss",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "exemestane induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151878994_T_C,C, 6_151878994_T_C,T, 6_151878994_T_T,T"
                        },
                        {
                          "name": "letrozole induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151878994_T_C,C, 6_151878994_T_C,T, 6_151878994_T_T,T"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "vaginal atrophy",
                      "eventId": "MONDO_0001433",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Inhibition/Decrease/Downregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "clinical",
                          "description": null
                        }
                      ],
                      "datasource": "Brennan et al. (2024)",
                      "literature": "38773351",
                      "url": null
                    },
                    {
                      "event": "decrease in total cholesterol",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "tamoxifen induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842246_A_A,G"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    },
                    {
                      "event": "Impaired development of, Reproductive organs",
                      "eventId": "MONDO_0021147",
                      "biosamples": null,
                      "effects": [
                        {
                          "dosing": null,
                          "direction": "Activation/Increase/Upregulation"
                        }
                      ],
                      "studies": [
                        {
                          "name": null,
                          "type": "cell-based",
                          "description": null
                        }
                      ],
                      "datasource": "AOP-Wiki",
                      "literature": null,
                      "url": "https://aopwiki.org/aops/29"
                    },
                    {
                      "event": "musculoskeletal pain",
                      "eventId": null,
                      "biosamples": null,
                      "effects": [],
                      "studies": [
                        {
                          "name": "anastrozole induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842246_A_G,G, 6_151842200_T_C,T, 6_151842246_A_A,G, 6_151842200_T_C,C, 6_151842200_T_T,T, 6_151842246_A_A,A"
                        },
                        {
                          "name": "letrozole induced effect",
                          "type": "clinical",
                          "description": "Genetic variation linked to this safety liability: 6_151842246_A_G,G, 6_151842200_T_C,T, 6_151842246_A_A,G, 6_151842200_T_C,C, 6_151842200_T_T,T, 6_151842246_A_A,A"
                        }
                      ],
                      "datasource": "ClinPGx",
                      "literature": null,
                      "url": "https://www.ClinPGx.org/search?query=ENSG00000091831"
                    }
                  ]
                }
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "safety_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "ac2b1dce-dde8-4042-955a-49a3e8384f20",
      "timestamp": 1761139325.21298
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CrASAdHtim_vjb_Z1j2mKOvb1z3WQ799QWsLYjOq3X-myyz52dGfuH6qCaL5Qvi3_CxflknoGNRdgZQpvhCic9NQZfrH7amXHKhJd4OAjyZNNInHBhy4vauwcFgVG-dVR7r4vt6XH_OMK1K3pj5HowaXm5z11zf_m31bXpmETGTaWgITVvQqy2cKmi_o3wsoiqklb-weMurNtyXfEsffda4JfBPWCoOc87USCHeGhUQCwvjxBR30uNwU4buDqw2Lodef-bHhv9XwNf3b3q3LyVJfOK05TvDigFPqcEauFDl6z5OChqBkEzAPJFWk_sEuOIeP0h9u7Yt4ld0guCp4c4kc4WqXCAfdHpjg1PM9Z88dJtNgDYhOAwev0mtVY5IxeTVmlJxHJQYqAou1RwKGOrQ4wYqUMTUqUJXcwLk_Zoeotc8rV7Z2LpwAuUutTaE5kuesaUOsSlaCa3q01N3JDBkWKnw8Wq65qwZYA0fq1w4dX2mrc3si9YhyL9NxdDApjLgZuSk3C7UaVhuPJUatJRP6mqpmCoeoopQ2B027SvIbZZyMgmA6npNg7rWTwVM-iFIuZD6yacCVNrh5DjMxvanveBxzmQk_jT3bPMPjNpO0RgGS4O_Gh6JJpQcfVoup2SLW-h0VTHAE3ptx1om2IiHELrppKGqc0hEbv0uPFd55qYw-dADGmLysV6cmIYaRsQKRZ-8GJWirmBDIGrgomWcj8oSs-AepUxIGjudMqqXktkCmgSj9hl9J6tlGbCoViL53taGEiVi0WwjaYlm6UR20856pCYBknRHj8Xn4DACNUfj-NnE5jnrky3G0I40QgoayX7_QzHLtZruyouhKOm2nJHyxu1zyWdunxszmNNZmwxRFV8gOXnjixxS7wWrdEdEk0pigwRQjORSL543So2m7InFwufYrUPpXtKamrepnuV-6WCXVyOjWK1dCY2jctVu6mU0UbaAS-jVwj8_pTTYuN5QaRcyw7mZwOW3eiILBQDG5x43YJUr5xMKjIyVnz0q1rKLPTdjhfCaJcZ_UQy9SXPq0S4uqSWxkHJ6EBD3InhQPlSXkKunzDcv3RD5KDczZZo1DwVA2PV0NfZ7QMj45Un-H80o-PR135hZiUvDUPWOAEGfce4xvg6ZUH7ei233UwOhQmVhsolnDpi2EPxy1fsmtcXMdKulIVH-PtMAE3fyujDhxoplp8wWlyt72pA1rLpCq6th-WLOkbZ8IQdpM2ak1v5H8MTWKvV-jjnqka4pDAI-N3D84aNXMwVmUhhID9Y6-JANAtEMIBNC-u2kwzHBB6BDsjynZUy8aRKMLiyR9Bqq4aeYsV04Jz_Qw3X_Q5EYifFP-6uq3-1F_9KYeZfu6guT-Com2mxNjQ9FlHM_yi-FQ0pcgb2ItypYxfBgsLyDKEh4fRvUJl69z2CIak0icODn92IKmegmLdj0nwlqQ0rYKQR139n1xXHkZUPQNMlxuAx3HsY9IUYxvGg_BdB3CR3hVkPCyoOcws2skaehiN5pRrle4IWUN7Pjj6USpp8acKs94MK32miWtJe0ki5Nx2tIohDoCic3HjkasCCFmGRhpPRvLx8zVeg5eg6oURMhqDhnRZI4OnrP03DECEgABtTkCBGD_jhN7hbxmIKdTSX3oyYCGMena9dAhH2AosHCON3eAzwnkqUYcKYY5DvUrsy8rq8o1-msnhR9cJeZ7M8HdDl8xlkE-BUhXSkhVD6xxs6Gnl_G296nBO3DIxB4GscmJSdALF2SqF8A1bADB77svQ4od4Emdm3LRsOcxN-jr71lNl3A6Wlpfd_qZISDGzebI6lkk4c8oJ5JpGi_wxoKBwbxyYoiAClQBnUPkgMJnv-HkR9jO7pioQzWcSeplMzjCO1uRE53tG38qlTUMsHtdFQ8cvURHyw6q-uEEeMtM5TWsep4YuNok2utakxVk2ZJnIILVtmFDaZFoFmFKcKdk7kqeVQrWJgFqEA3ejNeBDb82i_DYm5hwNIh5vFB3Ofb0SS-MWWhr2k2faTVSEB8XlHS2FDPWxqAXyYssiubbjUd6RPOya3vJmRlGRmEScuCu38wx8N5z2EGsQSVlkb16x-RrViYOQk9LHf3QM2zzdY-4d3FVtI0bht-u-dW1gP63JJtzVi9fZsSXYPPnxvuxsO2SC-BnHhjvWN0aXDyDo3mmaT41RjmJKgV7YNbzkePdbPtn5w7LEl_UwrMPc_BAfkYK-elR5xyDL_hucMh_3kEakSaXm6YUQBZI9_vIJ3frSmqz597dCYjvrp6z5T7DH42La1oX1JPekB0nhJH04qR4HScax_gZQ8Y6qzJ_DR779elZA69rTMXujBL_al5UT9ZCY736DIreuDnuNs-0A0ItVpaSzQgwaijPNnOoDuCewROeCI_D75v47VTcPROuJ9SX3YsbkcyLaHqjMZK13J0NVHZ3RhU9XEgChorLlUi9bI4WN3kLRvruyRfT6CLxo_C19hqNWU1HK_R9I6yFWSI15UDQHKvDt6CglmoUvdvXRtDtvvUwpbTi3YJqVzs_SwWVvRupuD6vMRLJ72YtKNoYegoW8pjMe4Be-vGSuSjQMvaw858icBJm45K6hwHNyXyY6sJylNexfCLR_-RZ5KAOF9j6P8PAahveU_dWCnhCH7aPOXTpS7B53hxM8eTLg1THBcZj1dHDCvTdoCVF45xAazIA5NDq7QfEjCanGyBRfe8PM0ZxQFptpw-3uX7-GQuPtcuoiBO8m5_S09Qaw5viGUlMq-6ULAVr-5OWmHES1NKG4Dw1MwTadN6W4CsnfVmJ1iCRO9ym8g67kleWvcZQh_r0Wo2c6BZVQzKLd8Xbx_3kxEpmVBKHQRmBJLk17uGIC_yAjipcyDWRG26VVrZEKgbIw8UXKkbkK_BXRvA5OlzvXDHSxuniVsFS-bBhExtSVWzkhIvHGzYY6sPt39y5mhjuOb27UjD2V5xuh8pK3_Th0XukmWcuc5W1xdHYZJC3ET-PfKbwppGi5Jek8ySF2FcDPkZMI_p8ETqKhXtRvqaFsngxgvqnfeNRZKi47tYHd1ANEDhypxUgqY6-UMHB8uKRjkdfLUwTxQy-QPjxHZ0j1vNftT8W3F8GVYZp7Rk-74SKbxdqQi1Z",
            "text": "I have retrieved a comprehensive list of safety liabilities associated with the ESR1 gene. The data highlights the central role of this receptor in hormonal regulation and indicates that modulating it has significant systemic effects.\n\nTo create a complete safety profile, I will now retrieve the target prioritization data. This will provide quantitative scores for safety-related metrics such as genetic intolerance to mutation and tissue specificity, giving us a broader view of the potential risks of targeting ESR1."
          },
          {
            "functionCall": {
              "id": "adk-de0bbce3-75da-4b48-aa89-e4790cf46353",
              "args": {
                "ensembl_ids": [
                  "ENSG00000091831"
                ]
              },
              "name": "get_target_prioritization"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "cacheTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 4006
          }
        ],
        "cachedContentTokenCount": 4006,
        "candidatesTokenCount": 122,
        "promptTokenCount": 13107,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 13107
          }
        ],
        "thoughtsTokenCount": 504,
        "totalTokenCount": 13733
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "safety_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "f97fe995-4898-4f8a-9eb7-5ae24b5e8fe9",
      "timestamp": 1761139325.217384
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-de0bbce3-75da-4b48-aa89-e4790cf46353",
              "name": "get_target_prioritization",
              "response": {
                "ENSG00000091831": {
                  "id": "ENSG00000091831",
                  "approvedSymbol": "ESR1",
                  "prioritisation": {
                    "items": [
                      {
                        "key": "isInMembrane",
                        "value": "0"
                      },
                      {
                        "key": "isSecreted",
                        "value": "0"
                      },
                      {
                        "key": "hasSafetyEvent",
                        "value": "-1"
                      },
                      {
                        "key": "hasPocket",
                        "value": "1"
                      },
                      {
                        "key": "hasLigand",
                        "value": "1"
                      },
                      {
                        "key": "hasSmallMoleculeBinder",
                        "value": "1"
                      },
                      {
                        "key": "geneticConstraint",
                        "value": "-0.734142305570877"
                      },
                      {
                        "key": "paralogMaxIdentityPercentage",
                        "value": "0.0"
                      },
                      {
                        "key": "mouseOrthologMaxIdentityPercentage",
                        "value": "0.4789900000000003"
                      },
                      {
                        "key": "isCancerDriverGene",
                        "value": "-1"
                      },
                      {
                        "key": "mouseKOScore",
                        "value": "-0.9363843084471015"
                      },
                      {
                        "key": "hasHighQualityChemicalProbes",
                        "value": "1"
                      },
                      {
                        "key": "maxClinicalTrialPhase",
                        "value": "1.0"
                      },
                      {
                        "key": "tissueSpecificity",
                        "value": "0.5"
                      },
                      {
                        "key": "tissueDistribution",
                        "value": "0.0"
                      },
                      {
                        "key": "geneEssentiality",
                        "value": "0"
                      }
                    ]
                  }
                }
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "safety_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "06a95fc1-e3c2-45b3-b3ba-f8fd227b94c4",
      "timestamp": 1761139333.873621
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "Cp8fAdHtim-TGSwmPspD1nAU2kEIh77Lh7VlZ5tsMcyBY1Mf0TvWA-KHhYjba0Eg1wXgkTv4wi3H339JlKr6Fnp3YMOz-maS9_r1SEe2S68eNI8M1i49fjvm9POGsDxukq1rUFl-WKMJ_7pYOsOoi_JyYzMbyvNW85Y1eau9Ig6W2ysQ54mLjYeGM5Ka4r-tlLQj5YTpRX93ENDuO24TfKiZmns0YwBzroEPQpD0jhuiUcLqeVorbJpUPgkTEJSnnOPuX5JfzfhSsQwkodMWoDc3-z_5GOwF0dqIbzADgicQdR0HJUU3AsYfZqQo3JlQLw_ntldQ2tMzQu4d413aIje1aDfYAoIEbBPMmqfHXTc8oyTo-xrO6QrdSjppNYPysYW_YiaisG3r5wQwoAMadIA4r76bncrwdzXpQAbxykxWq7SJM9OuIkyuNUlwGo0IWRUR6hfbt-ddq-tqM0dwzUCM4fqX4VHh2VM8w4Dc1ud80p4ezdsjHPl82fOWDfSl5losBE4FR8EB2A5tU1yi_s6xoo1M-dDhCwigPIxauvaYWH3ccGzEcQaHpI2gHQUmRGEO39SVckZeYI0ANhxfZxl6D8tsz_1KY3F3YZCK9mQUl_93Deqn4Ilc9mxi__0qw8zMBIuP2Apmi5w0NzSRMFYmPE7wcUfPvhvifX3BEX4fs_ki8JPEH0cpv-8h8GGIAKz6WCWuY-4QcWPKbZvluI-Xzjgf3hL1wDC-XTDzy0w1RGNX0MxKy_Ky3XfvsjWtp5jUFLxX6FO0Y_aMbEN60MZBnxZ_A5xbmIQYAUwgmwcVBmMgZ1qZWhYdMvS6csXDKBxxPy3VryCfTs3Aa0a-wi4uKZr51cQDzbcOCsR-1Rt8MSVO9XBTXvETIYlsv54miyloQPV89bL8x_4fy6lPuay7fMfZBBvNZarwLHrr5XiDqxn-YFhEvFD24JgMaSxzElIXgd1cC5vo2nrENA3TiHr1-Iji5QoUCT5z-U1zrpMMwpRtksboKrO3vGyOSyq4D9t-yzU4ddRoznKD_LbjVZVydhMVauuge7wo0LJmWVuydrdki6qygt4sjWvDV-x0rILToO4H0hln6OlC0GFe01rbBn7ZSqUzFTzA3TuPtMnH6ZbgIvIu2N3GCHv0IOwbaecOwK-Vuxlo5yLbKbaBLAJurnzeMuVglMpYUwMfBQ3OCSBvxdF7E8yaH38gkfRjot9sI0xs8HFJPeCJoSH0Uu7XZp3ALjyQWqxdWq1Ixg6rw3KkDzKTVQ4ZFe_ecIQLS0VKCMfjf906XF0HojT2NPh3QWYtTP4duBPh-iiU4ONEGy-qRYbagO5pVcl8EwHw7ZbPgvyWSc7wUSioljXEl8N7l58fDZQMF4CpwyDmSz3P1MTn8LVqZ9hbQBh4oimUtRhfsgUx2UitS32ABxOSys1G1vJO01rnNS2U8lsH33FFJ8z0j7ZZVVSoRRY3-L5jRmfcmpKEi7Z6KA2rVMxitiUVE1Tk71hnLZAsnl6XVheQOUjUFNX4g8AziMN-aY6p_k8UZVJkpR5YyyD8zbKoGEyjIPoam2KIgB7XBeLR5E4llAiMBBeArn2ACOENo_MkIzmXZ-WjBi0SmFaHoeH_cOqmmclgNJ3RC10uJwFs1Ju6tAvkDbLnJlehKbge1J-z-7NX7Na3_rPzyAMdAlYvyuh4F_m4loL8Fa5pImao72zgeuhYGsVajETI8S5IEy3oq3KegLswvy9Fl3lgaVbRGxhIaLRT-9RNRbzwYFLvs4g4mZfZodS5vPkO7bFEqn0Pc1U3MqfZBaMXrl9IhANXBFTlFFJUZiVGMCB8Ovqa05j6RfARFyAZxl7k0LKGUyrYUcGnHDBJKd55gigh3M36OoJ9_uxKOfYReLNsMMjZlkcQw0USbrmLp4Y_SjYAlu2I2B-85D63Y4q8GkKI70ttvX6h1ajyVOvBCtqtooxeSo1u7sLu010D84cJp_iuf1lw5kpP5G8l0q2LBFXUhfa963M6TvUmY0n6fCC5gSZxXf3XvlV-uytZ81KxMfmHe0jNG5hKBydkiOkOWv421wJYw9RZ-DOV6DXzZKBNQpg4dkfbXYl40Z2nBcLAMM9XnnPHLvQRIuX0CKr4bdbbsufu5CX5EP_lI3ZeOSXnYaFnWLBCsgrluO7vqoRAZlewn8zfauOlAR_rBfBZcMYyE7HyU7cjI64T8KbanBXjLKSeWjGDYUUHpEhba9fhYkgUz7JeAVVEx1PPWS8edaHiOgggQxf_GJZB8rsudulWh8e53bsBIveDTTKileeEV37cId2nsCbo5w9kctFVlZEBvUmaHycUfyydukdT5iZFfIsQT2Uy_SQja1eQlSv_FNlALRZ0nZeL1gqIj287OSRRgn5saimw69lX5aA067aXScLYAPzLQF7tBJqYf94xjD62C59ZE5473ApS5OzY9vt3PIUemTlFrtbEGAp8FeEvHo9iM_v3gnO8E6X4RuDV_2l_HrxKEVRaiZSFQxKp6ddZ9NwjN_qqDtAtJMPzG9I9WwBf6A0B1L_MCNl-19xPWhHfbs4sWEn8rHkBSb2IecT8ii6dkA1_dQCcHkl94pV6ux48I-Q_fALqyIsE9CQuUUSNijWPPdtWk4Dyxv6fzBE1fUk5uJUcg7nJSKUIFKxalgN6dm-AnTMeNX2Nj9wkOmGy4thRPVzp2U5PbksxC8QY10g9dzK9xcQ7NNaw1lwzoSfF8lhLppeKw9aZVXmB6b3F66ztgkwuE6YR2DzDP5cl0Z1hmzAU_NQ6p_fPHHlFBSrCuIwHcr0Y3c_RhFBZmH16g5x6jHhSx2aBE07_VaVWPWgH2YIiZTwxD3PNvW83qOJQ1ZFk545Wat-WbBqwf0D08QeCSGY35fOHskPalxwCC85MPT754gj2Buix-UpIu-Xv7ItbL2LL1OJ6SlOM3TD97Yn6WuEAJz7E3OVWZPMXJn5FKw6zye4NYs0np0Y_guYzPeGRqyTPF7xdqYXb0eP59mD2Ba1FnBW6Hdta6k-5BajFnHWOjs2cKHZsBA2Xy4JCXAnNahe7b5snXAA6rNWuA3X6__-BPe1eIsd6DKn0Dw07JBZDcBhbGjstsiDRu9ZFl3dUQPlGy1mCA4nlylH3vyd_sDB1z4L7TtQhVpCkQpvbP5YnAnAPCAxToUI2ltR5ujFN33nsCutSelZ_x1vS8Qs3rsuc8kD6iUKj3SfldWeBqy4dS1nqQuSBHsvaO3VYT1YMMsOzKh9kSHMeY0eRIdPRsSTXcpxVflSyetNWqiuzpTKVv0gmTFsAAZjJVDSSRF9ozboSyXFujxPkjyEOxBf4P5mYJfXHqP0bk8hAqbhoATJYR9KwfVwv2c5sFDdNpTta5z1thkLzwMU9Nl5eFlx4TWK2PeDqt4w4VRNI8LqRniFxxwlaSkIq56_Bfv6MKuZhNo1SSn4e2tBijegIh8IcsmFRQRlj2j7rOREe9gWqy9ezTOe9Z3QSGhnvkpD_gPOcgw2dF762oVgHGVwmdF8P-w9Dyg26dHqbJ9u_9pGhG49ZFHiCgP9UQQSaNucey95QWd2hOeydcxQM3cUnKxaM4pzJptGb2zXCurqdklBynrr7KHlPgRqeucxSgibJ1oYn_7B1AVOklMOIEKTMrZD6FPxMQA6kCBzybX4tf-hl7NtpmqpPUNbzK4ykDFaCsJrgb_TAfg2X967uMMIWmJRAbkdtw4cRTrl7ma-W3-ZvxwiefnJbSrKugdwwYSWW1tlm-vjbXy_cZ-mGKbENxXXBprAD9S7MiHZbolym1uv_f2lQ34hhxCynY1az3l6IpFc2ArMiOBVraD2KQCH3vnIEu_IFEbzBiuyrvH1hDzFXsuOJc0ssrU3x4KxVOw4JrPfRkZKS0P97vv_8YiWLZ6MQPztUJaaqcimhznosD7vxCgeCeqHOv0aWG-ArGipDVzqZr8cVO_1UeaAOtAJm3TKCs14if71zwGHe0qpNYjgRPGOK7RWhNn5LHSPbpneJBWVCIC_BzpgRFxJPk9m07CoVhWvuT7t5t7PUH9nnnM_g5Hka4QSc30y4XuaGeEuZVrm-Xz3AdJns9pVNsPs3bBoKmoX9VS3emUfvPgqNQJXiikkNf4iFzBOq_TIfr-qboOgH_ypgCADyKF9A72RMl_b52HQVVSFckbwud67NjAZetdsrdAhoEFSvmcShBHmb67aqjKrvD5XEBCnTIQSx67dNqHu6xOBqQ1oBFU8jC-pLH2LuoTLzircwRGPzR9VZWXumS5U_if2zMLYGddZJdBpKp2N7nB-RLz2ehwMg5jP_mHJc2uvtKNJ9H7JfPyu35CJDz7Dt3ODQRSW3ot60L8fA2BkbRJ3ob48iTpgrXNrOwj98TKsZCQ3ui9kt9SM6Dm3YzDmEuEwBhe6i_dqfjp2ax9H_a4zC8KWwTrw6u9BHk4hjdExz4OxRc4nLZPvgvP0_8UuRYEJXPySd1AS9N5FXfIAB8mgzquMykcewhYjZ_iGeHuOl9UDIgVmrvcrxr9Ua6E3KJtjizzKH-3MpY4hSdeNAVYPTdWTNEiApTQzQpLA1vhNDIPoh-R7f_wSGThkqOHqrFfy6VjZrP4FRmTR75GEomnhiA_UGhnhJtJov0DzG83Nd5C9PQmjcTfuGagAQC3bxjWiiBGE4nrUceYVVgzAseLv8Ors0SXYjF6eOzDb_I7ptXQ27698Fd0F6x_-gZQD28GWsRtAjhv6mPd-A435G232Ys8vbaz0y_JO_OE1z8yEdDRwM4O6t52h-TExBauzHhFLAQ-BqpsMUn9PgSYxvLEL04DNnpHPoPcmuTYvv2ALzy6HMsax2NMLYhSlLc-yTek-W5FOhhSSains7C2mwrhWMY-lho7O0CUiJw82NYtNub0zuaEdFTBY3wYBF7mUzzNRc7_hPG_PG_EEUi5oXalyGsgcw9RBKe72pyiEgupjG3bRa-F3pkJxOiQ7iRfePyzsSoWPGgLUOU_-yW0LCridp6wJqT9seHJik04Zkc0LS4GmBzeNf5uVi8mmo3kG2_tJ2VwgWH6HbT32-ODXDGmuK28aQ-Wqm2SdpLb2dy_WgghV8nM8pw6GP1z3wxidTrttDx8OU9GKWfRhnUfjQaWqaTkhvs6I7vRhUwnz86hadTKWtUA9QRUsF7nrGlf6-LEKRCc9N5RHKGhPKJ69kZdt6iO8OYTtHpVjVm_JKxIX9A7cFujZ2cBOIHCrbEmpUxvDKmRAjvufmOZftYq59vhkimC6_b7fVUevIxQtSaa5VzYVbPA68tcy_KFwbz8CogdGHbnRV64R6DTERcU6fLUAYGVNp0wYVbdahKqWM",
            "text": "Excellent. I have now gathered all the necessary data to provide a comprehensive safety assessment for the ESR1 gene target. I will now synthesize the detailed safety liabilities and the quantitative prioritization scores into a final report.\n\n### **1. Safety Summary of ESR1 (Estrogen Receptor 1)**\n\n**Overall Assessment:**\nESR1 is a well-established therapeutic target for ER-positive breast cancer. Its safety profile is extensively characterized and reflects its critical role in hormonal regulation. The associated risks are primarily on-target, predictable, and directly related to the inhibition of estrogen signaling. While significant, these adverse effects are generally considered manageable within the context of cancer treatment.\n\n---\n\n**Key Safety Liabilities:**\nModulating ESR1 carries known risks. For treating ER-positive breast cancer, the most relevant liabilities stem from **inhibiting** the receptor's function:\n\n*   **Endocrine and Reproductive Effects:**\n    *   **Common:** Hot flashes, vaginal atrophy, and breast atrophy are frequent side effects due to reduced estrogenic activity.\n    *   **Development & Fertility:** Targeting ESR1 can impact sexual development and lead to decreased fertility or azoospermia (absence of sperm).\n\n*   **Musculoskeletal Effects:**\n    *   **Bone Health:** Inhibition of ESR1 signaling is strongly associated with bone mineral density loss and an increased risk of **osteoporosis**.\n\n*   **Cardiovascular Effects:**\n    *   **Thrombosis:** While more commonly associated with ESR1 *agonists*, a general risk of thrombosis (blood clots) is a noted liability for drugs targeting this pathway.\n    *   **Cholesterol:** Modulation can lead to changes in cholesterol and triglyceride levels.\n\n*   **Oncogenic Risk:**\n    *   Conversely, *activation* of ESR1 is linked to an increased risk of **endometrial and ovarian cancers**, underscoring the importance of using antagonists or degraders in breast cancer therapy.\n\n---\n\n**Quantitative Risk Assessment (Based on Target Prioritization Data):**\n\n*   **Known Safety Events (`hasSafetyEvent` = -1):** This score confirms that targeting ESR1 is associated with known clinical adverse events, which aligns with the extensive list of liabilities above.\n*   **Genetic Intolerance (`geneticConstraint` = -0.73):** This negative score indicates that the ESR1 gene is relatively intolerant to mutations in the general population, suggesting it plays an essential biological role. Targeting such genes can sometimes carry a higher risk of significant physiological disruption.\n*   **Mouse Model Phenotypes (`mouseKOScore` = -0.94):** The strongly negative score indicates that knocking out the ESR1 gene in mice results in severe, system-wide phenotypes, particularly related to sterility and developmental abnormalities. This provides strong preclinical evidence for the on-target toxicities observed in humans.\n*   **Tissue Specificity (`tissueSpecificity` = 0.5):** ESR1 has moderate tissue specificity, with primary expression in reproductive tissues, breast, bone, and certain areas of the brain. This explains the specific pattern of on-target effects.\n\n---\n\nThis completes the safety assessment for the ESR1 target. My task is now finished, and I will hand the results back to the **Principal Investigator** for the next step in the workflow."
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "cacheTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 11605
          }
        ],
        "cachedContentTokenCount": 11605,
        "candidatesTokenCount": 680,
        "promptTokenCount": 13584,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 13584
          }
        ],
        "thoughtsTokenCount": 845,
        "totalTokenCount": 15109
      },
      "invocationId": "e-4e9fac4f-7618-45ae-95d2-f7293f37cf4a",
      "author": "safety_agent",
      "actions": {
        "stateDelta": {
          "safety_agent_report": "Excellent. I have now gathered all the necessary data to provide a comprehensive safety assessment for the ESR1 gene target. I will now synthesize the detailed safety liabilities and the quantitative prioritization scores into a final report.\n\n### **1. Safety Summary of ESR1 (Estrogen Receptor 1)**\n\n**Overall Assessment:**\nESR1 is a well-established therapeutic target for ER-positive breast cancer. Its safety profile is extensively characterized and reflects its critical role in hormonal regulation. The associated risks are primarily on-target, predictable, and directly related to the inhibition of estrogen signaling. While significant, these adverse effects are generally considered manageable within the context of cancer treatment.\n\n---\n\n**Key Safety Liabilities:**\nModulating ESR1 carries known risks. For treating ER-positive breast cancer, the most relevant liabilities stem from **inhibiting** the receptor's function:\n\n*   **Endocrine and Reproductive Effects:**\n    *   **Common:** Hot flashes, vaginal atrophy, and breast atrophy are frequent side effects due to reduced estrogenic activity.\n    *   **Development & Fertility:** Targeting ESR1 can impact sexual development and lead to decreased fertility or azoospermia (absence of sperm).\n\n*   **Musculoskeletal Effects:**\n    *   **Bone Health:** Inhibition of ESR1 signaling is strongly associated with bone mineral density loss and an increased risk of **osteoporosis**.\n\n*   **Cardiovascular Effects:**\n    *   **Thrombosis:** While more commonly associated with ESR1 *agonists*, a general risk of thrombosis (blood clots) is a noted liability for drugs targeting this pathway.\n    *   **Cholesterol:** Modulation can lead to changes in cholesterol and triglyceride levels.\n\n*   **Oncogenic Risk:**\n    *   Conversely, *activation* of ESR1 is linked to an increased risk of **endometrial and ovarian cancers**, underscoring the importance of using antagonists or degraders in breast cancer therapy.\n\n---\n\n**Quantitative Risk Assessment (Based on Target Prioritization Data):**\n\n*   **Known Safety Events (`hasSafetyEvent` = -1):** This score confirms that targeting ESR1 is associated with known clinical adverse events, which aligns with the extensive list of liabilities above.\n*   **Genetic Intolerance (`geneticConstraint` = -0.73):** This negative score indicates that the ESR1 gene is relatively intolerant to mutations in the general population, suggesting it plays an essential biological role. Targeting such genes can sometimes carry a higher risk of significant physiological disruption.\n*   **Mouse Model Phenotypes (`mouseKOScore` = -0.94):** The strongly negative score indicates that knocking out the ESR1 gene in mice results in severe, system-wide phenotypes, particularly related to sterility and developmental abnormalities. This provides strong preclinical evidence for the on-target toxicities observed in humans.\n*   **Tissue Specificity (`tissueSpecificity` = 0.5):** ESR1 has moderate tissue specificity, with primary expression in reproductive tissues, breast, bone, and certain areas of the brain. This explains the specific pattern of on-target effects.\n\n---\n\nThis completes the safety assessment for the ESR1 target. My task is now finished, and I will hand the results back to the **Principal Investigator** for the next step in the workflow."
        },
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "0ab0613f-04cb-4833-ac82-a67ea81df6f9",
      "timestamp": 1761139333.880728
    },
    {
      "content": {
        "parts": [
          {
            "text": "continue"
          }
        ],
        "role": "user"
      },
      "invocationId": "e-95d6cdb5-9075-4f1f-a33c-2eacf0e2c344",
      "author": "user",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "bd8b0dc3-87a4-4193-903f-1f5e9d185a91",
      "timestamp": 1761139451.504366
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CvEOAdHtim_Yw8ZkMP60ayHFf_mKbADbYzWNQHqtchttzTjIf4uHqYs1ktNhLdHnI5t4DBSwj5M__8G2V9bcAjyZvaPis27f3Yxa457znXHm53EenW7S5MhTFYdsq-Qg9ZOzQ4WrfD7co_1uJjVljXf1XFFHbB6PUMAwioG8V0zzS49lYbxnYS9QNjX2lphIaiKNPFCalCIiLndkpj3bUfe3kO5XXfgAmqUVdg4V2X02B4F2a7dnOVrQw6Gry6rna7eOURkMcxzseAAYnoguuxQ84RHtUT3A1C3l2lvXGzFwWo7qi0n95REiCyKVNriPI90d3MIIHnvCpwtymXPnQvIRupknGAbZkjSC0Op_h-dobk9RkdqHBlvJ4VJEns4pukJ-Oh0hfCrUGYULn4LfvMpe98GNrVike996EQ1zMH1LZZKrWtcUVsvU8Fkm9H7tHRaJgaT35mAZs5ucE_WhPjLZ4t3xCn1oKgObekb_AIUnZf8EvLS8gUcok3l7hO7QcI9wWM82kHB1ItLwzZXMZXFOFZoqF5n-I135x75yr3rjxV6HPXoHytc5ncATm_fJs5RojtjtWgohQEB2mTrDXxBSfsSj7WpUtFhHhhr52cmAdEKhml8Ib-xrZyDljWLdEXAEErMSwcSnTRsrVGS3WH44R1qBTYRirIwqQtC0_tQ0ARRsSO249lEA4HWBZEFwecFLNyxklmIS6GpthDfnjhnTWul2qavpVdXuYDb4Gn4IkbqlNZoKnQd-wkyjRNDySdgc4TCxDKY0W6ZY9-aa25jIoqmv7ZFrSJUSvGxg9Ck4RmPs4x1gqGEQfzeQm3qJHODhZBp7OSR2x5m5hjHUtjE6UzcrcjdqhXkyc_filabrA9R43qYsnghpZ63kXTuAv4Qm2EHhajV8LSKVWsQ66eEeRN27PpB9GFP90sva_BFJL9h2NNF2h1P3OmU8Y33_Y0VWJHJFoV0Q-T7anbAktGqGxNf__yGrnovdi_h8HtIuBZj0gsQYRCYNsQUxfisrpry_D2mkQFvR1rbkwLlHspkXdVPxxUtgY9a7vO0DZ9r0UJtuSXQ3Ea1f7EawwBETyIBYxb1S6rEF9hmCMDJK2zlcV-FSPIvr6oYALjk8lEDwp_UTWo2POsFzA4UT9JbX8AQlYVcWyf8uF0RqiQ4SHrHA-Vl5dtjeEGxudc65J39bHhD4PGv8VIujcWMyqA5umfQYVDWGGSCsO3WXtYMdmslrOG1Oo1hYTFVuuD_u95-nE4-TBq0pTdaFpVQiX7_9pQ4PGrtoZ3vp12HEr_Cy6nmTlUFr7Vay3SUvONVpzGrX4Xrijbt7JuFZ3pMsgtcfU0VxC3NP5jyVc6AraA9uExj7BL3YpQdnyJEBmmY4mW_m7SRkcd-rGegt6XfidXNjlnBudThpabxnjf-KQg227dUNgYrdnvuXtGhUoDQzXRn5SVqTv8kFLn4X6NkuG1RcElnddkZ-f4BLRMh0aWIVeIhNmd0eSBc6LHjqpvBjB6OBA5-YSTRo5MCD1cUNdMpEkBCOhRtCkJ0OCHyOxbfjJY8C0ay-FqUOgRuS2_NIzKUJgBSfIN8I0Dm6BA1WIWr1u5x2xfJ_1zcEZvBnXpduloLWwXQTQaBd7SBkK6N2w41AbNM_p4E-mweTsj56WQV8gKTIDYnD61RheYqkRfkEhoTg5MN8PuoPvha2hDtDqKYdRPcE74O4jU7iltSIIT_qk495ClzbXV3puVGFg-PBpQWCQs-dTWKtJrAN454OXc1u6vp5SU4WU5jbGJAMVWopZqVC-PVRk119q8eJcrYwb-AECQihFPjEzKoww96eskvv8VgrXd6h2_aaf-1MbDET12Nx-ELK3effhg2Gqu6xPntzDYZNJAQCWnuJv6rArfxLVgrL_tvkDZvzaw6EQC4MGBIYbu5hsoD6Y7Yus3-3xD_X5csgAF5zlhClWkgeqzrDIwaut5fg02RMO-cPlhN9GHcditgq9ZvaydRgIQSLvCXD3D6IS1WFJIp4AzgrVEvXTqt6rMQM0HxIXUvGXxH9U3oEqgfLNzDfZFJr73eIdOjAZCijANnONJzVe6u0z9jy-4377uVr5Qxr9QrtcFX34NQL-GFfiNfdCXnEzFMuA0jcxtxDPI_1izB9q_JO958FZHFmphguk3zyhsMbcB77b68XOC0Arv3ii-BRCeUgevC4mdftqTDloxOMm_a5iOuBOWIGn2Z2LxuEW8KF1NyHJXy6plpHDhgU3CGxKSHFNk2rC_K4IHZDqatMHJTv91Z0f8GIvwC_4vDTbKpPlp2QX_75Jqw-3sNgHykVoiYc-IRgLdAFS143_LUcbc65zXGRBMQ8PCKNQkbjG0LHZe2z7ropSuyU0AJpJzQI5NUUWSJh7jyJGl56WywBnkrwhQlpnYSmI-YcFkBO-ycUN7MEh0Bkw_vihdK5Y-5v1-VS-8ww6FKNtK8gb9du5v8fJuJQTz05CWsyrTozfNkQ5Rid-p9rcFD9MpbG8PHoJpsA3Bh2bbddzXbNu_OHRGSrWEJ0OYxD",
            "text": "Excellent. The Safety Agent has provided a thorough analysis of the ESR1 target.\n\nLet's recap our progress:\n*   **Step 1 & 2 (Data Steward):** We identified **ESR1** as the key genetic target for ER-positive breast cancer and retrieved a list of drugs that modulate it (e.g., Tamoxifen, Fulvestrant).\n*   **Step 3 (Safety Agent):** We now have a detailed safety profile for ESR1, confirming that its modulation carries significant but well-understood risks, primarily related to hormonal and endocrine disruption.\n\nWe are now ready for **Step 4** of our plan. The next crucial piece is to understand the *biological rationale* for why combining drugs could be effective. For this, I will delegate the task to our **Biology Agent**.\n\nThe Biology Agent's mission is to:\n1.  Explain the biological role of the **ESR1** pathway in driving ER-positive breast cancer.\n2.  Propose a scientific rationale for a **combination therapy**. Specifically, explain why targeting a complementary pathway, such as the cell cycle pathway involving **CDK4/6**, alongside ESR1 could lead to a synergistic and more effective treatment.\n\nHanding off to the Biology Agent now."
          },
          {
            "functionCall": {
              "id": "adk-5f3d9e36-558f-4f74-9a3f-094877f18162",
              "args": {
                "agent_name": "biologist"
              },
              "name": "transfer_to_agent"
            }
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "cacheTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 4124
          }
        ],
        "cachedContentTokenCount": 4124,
        "candidatesTokenCount": 285,
        "promptTokenCount": 14267,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 14267
          }
        ],
        "thoughtsTokenCount": 432,
        "totalTokenCount": 14984
      },
      "invocationId": "e-95d6cdb5-9075-4f1f-a33c-2eacf0e2c344",
      "author": "safety_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "longRunningToolIds": [],
      "id": "f69faa96-0681-4ca7-8127-2c0c33e8fc62",
      "timestamp": 1761139451.506789
    },
    {
      "content": {
        "parts": [
          {
            "functionResponse": {
              "id": "adk-5f3d9e36-558f-4f74-9a3f-094877f18162",
              "name": "transfer_to_agent",
              "response": {
                "result": null
              }
            }
          }
        ],
        "role": "user"
      },
      "invocationId": "e-95d6cdb5-9075-4f1f-a33c-2eacf0e2c344",
      "author": "safety_agent",
      "actions": {
        "stateDelta": {},
        "artifactDelta": {},
        "transferToAgent": "biologist",
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "8876626b-9e1a-4a45-ae96-f602d8ba313e",
      "timestamp": 1761139460.548556
    },
    {
      "content": {
        "parts": [
          {
            "thoughtSignature": "CssWAdHtim_m29k37TwPQeoBRY-asC-jG5eTxaTCBJAtzV2_kZtlzxXU9v9L-gXUKBIXW732zpaoDVgQMMUjxl6Z0ESkgl8Pcv3ioUGv6Zf7Qq8iOWUqyDWvn2bhRrMZXuOmaga73haAhEw1OUrKdd5EqqOS7GP9Ekva1jX0jUObKF0X_O7GiSrWake44V3XDtdTSZu4GtHp1ZLRLN5y53aKAOabz0yF5k5EdGRxNW61dxr7MmF6y_HFjfMTBaSxtv_IFcUDe75U75jtIqqmysKYBv3yc0PtjfuQEDEuFCetthoSdALKItwXW4_7kGZO5idPViBEVLvrxKT-4IhYunSlJnAtatjF2nN88-h0MY7A5lRhPD4IrbCcMC2Kwf3uU00FC76059Marqad0pcjc4gkwz2SGri4UT3QoLz3-0jjxfJtRDhO2LyH0Cj3WB4rIspl_LXsvR37N_qitZT_tdk98tgl9zmv2s3lJ3l_uGlOq8ODu6D4mIscnCoD9TFsp_oiZDfFQEoKiLSK5gsPfTBvml6hbyLPiRICAgei6DK19jSE8Vb5hflMPza7a4xEt2nAeL8tkzekK3unVC-7xIYalhXa-3mpjhUYWTb-p_D1aAS4mx45vGrf6CN7SKluZpGGbyUeAWEC0n2-gQFlFIqBg0gH4Ico5sMxbkMvY-cIwtEpYAoY-ew68EZovBjXQX08njSHy6Miy9WKXzQ7kvXImFZKDEv-l3K0xVa2X6IMKAzxcWfZcOULt_lzV3PzgmbA1cSAlRAFUJZeTFuRYLB39IRpf43iisEm9229OeGmnQNsBa3m_gekEoNzFYAatadunJNBinldF85nXfivTfVXZelMn-t37Jv-WIs4T4Z1Mn7Iv7qk41L82k7LW5bZhjFyY0z1Cfqcx9cNWtFAx1IVFiSmlhJ8uuKBWmBoVchfLZesDFN38WDym-kCCfKRBBDVSv3RtRKD3o_C-Bk3sFSRrxmaIiLmdDrkRcRtSaTN2r97ASIq3Z26pA0DXTxkokqAB7XMIXhO-D5BQ44N_INY1z0OV9183g4n5nitMqivzY0ep7Qkn2A0en1w6RW5O1RkxBaR5s9hq-S6aeecKd2ee2DKWBY6m11D-hGwG3XDqLLagj46ucgW-Mjb2TdI0hhXEj81C7xmu_PmWpcALR-ec5FtO6mXX8QepdavdTAIFAVcI68OBFYz2zvxDt23G1vkZqQ02g-SDk6XqvuV_Sn5isFNElwL_vhS2sV1foJFXZ83__uBjl4TPxdj84-pLbURmHTUhcJ4GCf0omn4rypgIPf9jW-dFzVuJk3oGeVpOqvv7EimMNc6IADfrcVpZvWxrD5nFLKlQ4l7JIGUYr9UvD1UBkoTvDoPHDfDGd6a8O7cFC0kcbzd6E9TLZRMXD7Q0v1XEzaC7Cem7KHCB7huKEglMd-gI2nrZ7PTNiBTiOVvGaznsPB8FNPfze6T2t99_mJVL_OI4G-q5JOtyK3qHo3bVTYLa0Qes0qYLNXeZdQS_CsHKowz8Kd7t4iy2WKcUCgsoLs5D0noPUj_ZU3iyM34aqOuJUEO6bO6obH_EjEX8Gg-6uNE9V8Zt1QeUmOHhvcz9_7qdybYsrlWYMdLLF8Vsn_79pDRIUlWoh2B3eR0CsWn9kDPRK1VBrOTtVIC1toaX8f1iNGjy09ZsWW1jKkJLsreYdVy2TLVOHiPVTvucqJf9SrxcNBNLrF9lFMzb-HmtAAIh1VQ1p4ifnEOayWHeUA86kBmLXhspjATKKK6ij_YAjGN1w1dXdugP_pP2KiL2J7Xy5_qxaoOOvzvvPor4vX-YRg2dNuiHAtKlHZycBILZm9-NRRcvT2swF-H7hl_Ax516WcA0X5dFdddhKLMQN0skLDoHdgLJcpdgq1_iuTpZ7pKwEfbR0ZHcZkbeCUGCq-H8SE1ChT72h3fLEZViz6ZtzfC0SNbfo-agO1Dv5MxiYZmXMMbQ-2iglvp5K_3SEqpXT_K49bjRp3WOolNq711UE-YcQ7rrOME-oZLkYTUZFN9_WSzymM2SFspDTzfNg3qC9OvQmeHGUrB0YIsQzW1W-xNdZMEnrxwHDuiN-6a2g2bjipSaG5An4RgPmMzv3gGO6Tsgwnkhl2LKnH4pyqTLnPaK2loIjcaj2BlTqJPhtmu0w2gPCbdySEWHiSC6dflUDdR_UC1FGQ0EcYBwCgQMNh4tmTavJPeLkEeKArMWqJm2puSuWC05w18g6wlufgEtnjQYaR7Ce0bbd7D5MGytyjmIQeQBwwSxyuJy5yIDogA7YnLe5yzwgQZTgVtYPJam3bHf9jGKhFFgkm2XPwCRxiMr1ygPXTb03ZUkue_SSRUYj-Iyjb3a2QBocuxl3FghggzujMt4XGDrV847iRhBLdmn6DRxxkSyI9XoVQKPf3Jtm1rxHYaSQVs1OkCFIBrLZTxBVpB-u6wyaU4EFt2nz9WLAF-j0Voy6PobrUXEGn4w2f8aKtQBYNosgQk5IfswZmawSBmcsrO8RwVEwv2g9QrMMWzE7kATiC7q7RSmbJTeVE_I-KnOnoo1DEFcXtnYkNyDzvo0BnBSAgd3Acj5k3r3gYc3Mo_phbdyXynG78sAOtQUJJS088Ys5Kf_WEeeRcUmUY9wMuxzf_Ex-N_K59q6EItZbHfCL3eCNwHcZruk_YlEL276RrBYk9-dt1bri9W1kva2FrH0jGNpVe1tXMMzEF_kiDN0x__DxcAPHJXumZDGEZ2eocyKwwQRNNYIsjtpHCMuUlN52bdOveDQmikStr9Mixs7fe_W-wlEtiZD5kc3dSkqOYgbQsS-HyLtIhEXzAaZLxbTFQNUwQSMl1x3mOLav7UDw_4qFHga6QdQF35zHKwJzvXddCOu-XiUVZWu2T7afRgKYCm44Kvsh2aYKGcrGOwzur17Uw76k0A51njnXD4GCKAhSlqr7waCRVORalsc5ENAqkiJSxR2Bxh7iQe3T26IRlihVwR23Pkcv9e1VltVBEDNTkbA_Tj2CPedcrQsITo60fHlj3V9sRdFsZekX13Stt4kzPc56k3ZcXDTNbHW2vUNmHnZqKJrGMuL3adocf7f5L4tdnsvi-RnmTjwS667m1S82P678CVRac8UJrdRxHiPfWxdS4c_W3_4FF-mo_-Qm4OH1f7VUf5zLOClrEt41cbb3kf7IKi9OKrDMjm3Y7ukrjWGXelZJGHuufH4985GQe5y7RDGGqexPhB858nGEaPCVvukZuTwSL4tyQlqfhUMhYua_OA2nGCVxGQS2dXBEkJuaX5Ri_nfDcCuKuqG_KTlUMSI2jm3JBULsONo87JLjXyefiBOXPVj78kM1TWv-HV8x-pirVK7f8tgJyBTFN4kY6D8kZaNO_k6qXUAeiMJKHOMYqAEOBYBjFi5h8lpmB4v6B6G8RElbOOn1NWgNgsFTmZjCXDqFgrU9Rd5KsmWuE_gq-8CsvBV6amxM7dLgyvP__e60_70h-bHzcz5P4tq3Qt94WwChKRtPBZp0JViKlOG4MV3Le-3P59DYZmNaXXH1g8YFQeAZ0vOmK2lHeULY2MmVosWC9aMnzeS7dyLXkoWUL5sdZiW60_0LvUFsOVoA5ednepbFLfqEm956iBYkwS9sMGsNP9YSCf96taigZEbfX1O_e5UgkizplDG8tP5nblFWTLeYhwILzgrc2fStX5W_cVqzJIQl9Guck-T-3wj7PoT6bqI5xvvasT9FAB9OnTAPmUlAIxUWnimF5ce_oy3_sSs6iLSjrlV0hz98tBNGnTSD1zOhilRCUuzwd2NgJFGYx9qNh7qpCArC5xx5GEpMZOPBuU1fXIFeQr14BtKL2hefhkSVo=",
            "text": "Excellent. I will now provide the biological rationale for targeting ESR1 and the scientific reasoning for using a combination therapy strategy in ER-positive breast cancer, as requested by the Principal Investigator.\n\n### **Biological Rationale for Combination Therapy in ER-Positive Breast Cancer**\n\n**1. The Role of ESR1 as a Primary Driver**\n\n*   **Mechanism:** The Estrogen Receptor 1 (ESR1) protein is the defining feature of ER-positive breast cancer. It acts as a **ligand-activated transcription factor**. When the hormone estrogen binds to ESR1 in a cancer cell, the receptor activates and moves into the nucleus. There, it switches on a specific set of genes that drive the cell to grow, proliferate, and survive.\n*   **Therapeutic Implication:** Because estrogen signaling via ESR1 is the fundamental engine of tumor growth in this subtype, therapies are designed to cut this fuel line. Drugs like **Tamoxifen** and **Fulvestrant** work by either blocking estrogen from binding to the receptor or by promoting the receptor's complete degradation, effectively shutting down this pro-growth signaling pathway. This approach is known as endocrine therapy.\n\n**2. The Scientific Rationale for a Synergistic Combination with CDK4/6 Inhibitors**\n\nWhile endocrine therapy is effective, cancer cells are notoriously adaptive and often develop resistance. A common way they do this is by finding alternative ways to activate the cell's division machinery, even when ESR1 signaling is blocked. This is where the synergy with CDK4/6 inhibitors comes in.\n\n*   **The Cell Cycle Connection:** One of the main downstream effects of ESR1 activation is the promotion of the cell cycle. Specifically, ESR1 signaling increases the production of a protein called Cyclin D. Cyclin D then partners with and activates two key enzymes: **Cyclin-Dependent Kinase 4 (CDK4)** and **Cyclin-Dependent Kinase 6 (CDK6)**.\n*   **CDK4/6 as the Gatekeeper:** The CDK4/6-Cyclin D complex acts as a critical gatekeeper that controls the cell's decision to divide. When active, it phosphorylates the Retinoblastoma (Rb) protein, which in turn releases the brakes on the cell cycle, allowing the cell to transition from the G1 (growth) phase to the S (DNA replication) phase, committing it to division.\n*   **Rationale for Synergy:**\n    1.  **Dual Blockade:** Endocrine therapy (targeting ESR1) shuts down the primary \"request\" for cell proliferation. A CDK4/6 inhibitor blocks the core \"machinery\" that executes that division. By targeting both, you create a much more robust and durable blockade.\n    2.  **Overcoming Resistance:** If a cancer cell develops a mutation that allows it to activate the CDK4/6 pathway without relying on ESR1, endocrine therapy alone will fail. However, a CDK4/6 inhibitor will still be effective because it blocks the pathway further downstream.\n    3.  **From \"Brakes\" to \"Full Stop\":** Targeting ESR1 puts the brakes on the cancer cell's growth. Adding a CDK4/6 inhibitor essentially puts a wall in front of the cell, preventing it from moving forward in the cell cycle. This combination has been clinically proven to lead to a significantly longer period of disease control compared to endocrine therapy alone.\n\nIn summary, combining an ESR1-targeting drug with a CDK4/6 inhibitor is a powerful synergistic strategy because it attacks two distinct but critically linked nodes in the same cancer-driving pathway. It both shuts off the primary growth signal and disables the core machinery responsible for cell division.\n\nMy analysis is complete. I am now passing control back to the **Principal Investigator** for the final integration and summary."
          }
        ],
        "role": "model"
      },
      "finishReason": "STOP",
      "usageMetadata": {
        "candidatesTokenCount": 789,
        "promptTokenCount": 13592,
        "promptTokensDetails": [
          {
            "modality": "TEXT",
            "tokenCount": 13592
          }
        ],
        "thoughtsTokenCount": 645,
        "totalTokenCount": 15026
      },
      "invocationId": "e-95d6cdb5-9075-4f1f-a33c-2eacf0e2c344",
      "author": "biologist",
      "actions": {
        "stateDelta": {
          "biologist_report": "Excellent. I will now provide the biological rationale for targeting ESR1 and the scientific reasoning for using a combination therapy strategy in ER-positive breast cancer, as requested by the Principal Investigator.\n\n### **Biological Rationale for Combination Therapy in ER-Positive Breast Cancer**\n\n**1. The Role of ESR1 as a Primary Driver**\n\n*   **Mechanism:** The Estrogen Receptor 1 (ESR1) protein is the defining feature of ER-positive breast cancer. It acts as a **ligand-activated transcription factor**. When the hormone estrogen binds to ESR1 in a cancer cell, the receptor activates and moves into the nucleus. There, it switches on a specific set of genes that drive the cell to grow, proliferate, and survive.\n*   **Therapeutic Implication:** Because estrogen signaling via ESR1 is the fundamental engine of tumor growth in this subtype, therapies are designed to cut this fuel line. Drugs like **Tamoxifen** and **Fulvestrant** work by either blocking estrogen from binding to the receptor or by promoting the receptor's complete degradation, effectively shutting down this pro-growth signaling pathway. This approach is known as endocrine therapy.\n\n**2. The Scientific Rationale for a Synergistic Combination with CDK4/6 Inhibitors**\n\nWhile endocrine therapy is effective, cancer cells are notoriously adaptive and often develop resistance. A common way they do this is by finding alternative ways to activate the cell's division machinery, even when ESR1 signaling is blocked. This is where the synergy with CDK4/6 inhibitors comes in.\n\n*   **The Cell Cycle Connection:** One of the main downstream effects of ESR1 activation is the promotion of the cell cycle. Specifically, ESR1 signaling increases the production of a protein called Cyclin D. Cyclin D then partners with and activates two key enzymes: **Cyclin-Dependent Kinase 4 (CDK4)** and **Cyclin-Dependent Kinase 6 (CDK6)**.\n*   **CDK4/6 as the Gatekeeper:** The CDK4/6-Cyclin D complex acts as a critical gatekeeper that controls the cell's decision to divide. When active, it phosphorylates the Retinoblastoma (Rb) protein, which in turn releases the brakes on the cell cycle, allowing the cell to transition from the G1 (growth) phase to the S (DNA replication) phase, committing it to division.\n*   **Rationale for Synergy:**\n    1.  **Dual Blockade:** Endocrine therapy (targeting ESR1) shuts down the primary \"request\" for cell proliferation. A CDK4/6 inhibitor blocks the core \"machinery\" that executes that division. By targeting both, you create a much more robust and durable blockade.\n    2.  **Overcoming Resistance:** If a cancer cell develops a mutation that allows it to activate the CDK4/6 pathway without relying on ESR1, endocrine therapy alone will fail. However, a CDK4/6 inhibitor will still be effective because it blocks the pathway further downstream.\n    3.  **From \"Brakes\" to \"Full Stop\":** Targeting ESR1 puts the brakes on the cancer cell's growth. Adding a CDK4/6 inhibitor essentially puts a wall in front of the cell, preventing it from moving forward in the cell cycle. This combination has been clinically proven to lead to a significantly longer period of disease control compared to endocrine therapy alone.\n\nIn summary, combining an ESR1-targeting drug with a CDK4/6 inhibitor is a powerful synergistic strategy because it attacks two distinct but critically linked nodes in the same cancer-driving pathway. It both shuts off the primary growth signal and disables the core machinery responsible for cell division.\n\nMy analysis is complete. I am now passing control back to the **Principal Investigator** for the final integration and summary."
        },
        "artifactDelta": {},
        "requestedAuthConfigs": {},
        "requestedToolConfirmations": {}
      },
      "id": "e08d2fa4-e825-4f55-8c66-86bcca807d78",
      "timestamp": 1761139460.552946
    }
  ],
  "lastUpdateTime": 1761139460.552946
}